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ABSTRACT 
 
Mammalian circadian rhythms are controlled by a clock located in the 
suprachiasmatic nucleus (SCN). The mechanisms through which light phase-
shifts the SCN circadian clock are similar to those underlying memory formation 
and long-term potentiation (LTP). Several secreted proteins, including tissue-type 
plasminogen activator (tPA), plasminogen, and brain-derived neurotrophic factor 
(BDNF), have been implicated in this process.  These same proteins are 
important for photic phase-shifts of the SCN circadian clock. Early night 
glutamate application to SCN containing brain slices resets the circadian clock. 
Our experiments find that the endogenous tPA inhibitor, plasminogen activator 
inhibitor 1(PAI-1), blocked these shifts in slices from wildtype mice but not mice 
lacking its stabilizing protein, vitronectin (VN). Plasmin, but not plasminogen, 
prevented inhibition by PAI-1. Both plasmin and active BDNF reversed alpha2-
antiplasmin inhibition of glutamate-induced shifts. Alpha2-Antiplasmin decreased 
the conversion of inactive to active BDNF in the SCN. Both tPA and BDNF 
allowed daytime glutamate-induced phase-resetting. Together, these data are 
the first to demonstrate expression of these proteases in the SCN, their 
involvement in modulating photic phase-shifts, and their activation of BDNF in the 
SCN, a potential ‘gating’ mechanism for photic phase-resetting. 
   Using western-blot analyses of SCN tissue maintained in vitro, we find higher 
tPA, plasmin and mBDNF levels in the SCN at night vs. the day. Also, in vitro 
glutamate treatment of SCN tissue during early night increases tPA levels to ~2.5 
  v 
times control levels, while similar treatments during late night and mid-day do not 
alter tPA expression. Glutamate treatment in the early night does not alter PAI-1, 
plasmin and BDNF levels. Co-treatment with glutamate and PAI-1 decreases 
plasmin levels (vs. glutamate treatment alone), while co-treatment with glutamate 
and alpha2-antiplasmin decreases the amount of pro- and mBDNF in the SCN 
relative to glutamate treatment alone. We also show that mBDNF levels are 
significantly lower in tPA knockout mice during both day and night. Together, 
these results support circadian clock modulation of BDNF and fibrinolytic protein 
levels in the SCN. They also suggest that glutamate modulates tPA expression in 
the SCN, while tPA and plasmin modulate BDNF expression.  
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CHAPTER I 
Background 
 
Suprachiasmatic Nucleus (SCN) and Circadian Rhythms  
 
Circadian rhythms are biological activities that oscillate under constant 
environmental conditions with a period length close to 24 hours. The 
endogenously driven circadian rhythms regulate the biological processes of 
diverse organisms ranging from prokaryotes to mammals (Kondo and Ishiura, 
2000; Sharma, 2003). Patterns of brain wave activity, hormone production, cell 
regeneration and other biological activities are all linked to this 24-hour cycle 
(Rivkees and Hao 2000). 
Circadian rhythms have three key properties that can serve as defining 
criteria: first, persistence of an overt rhythm in constant conditions with an 
approximately 24h period; second, temperature compensation—that is, free-
running circadian period lengths in an organism are very similar when measured 
under different ambient temperatures; third, the endogenous rhythms can be 
entrained by certain environmental cues. Under entrainment conditions, the 
period of the overt rhythm equals the period of the entraining cycle and the 
rhythm maintains a stable phase relationship with the entraining cycle. Also, if 
returned to constant conditions, the free-running rhythm continues with a phase 
determined by the entraining cycle.  
Multiple environmental factors, including light-dark cycles, temperature 
cycles, or other stimuli such as social interaction can serve as entraining cues. 
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Among them, the most important cue is the 24h solar cycle. Light pulses or 
transition between light and darkness can shift almost all circadian rhythms when 
applied during certain phases (Reppert and Weaver 2000).  
 In mammals, the primary circadian clock is located in the suprachiasmatic 
nucleus (SCN) of the hypothalamus (Moore and Eichler 1972; Stephan and 
Zucker 1972). The SCN is located at the base of the third ventricle, dorsal to the 
optic chiasm. Based largely on peptide expression and neural connectivity, the 
SCN is divided into two main regions: the core and the shell (Moga and Moore, 
1997; Leak et al., 1999). The core is located adjacent to the optic chiasm, 
whereas the shell is the dorsal-medial border surrounding the core (Moore et al., 
2002). Despite inter-species differences and overlapping expression, 
vasopressin (VP) and vasoactive intestinal polypeptide (VIP) immunoreactive 
neurons are generally located in the shell and core SCN, respectively (reviewed 
by Moore et al., 2002; Morin and Allen, 2006).  
Individual SCN neurons are self-sustained clocks. Both core and shell 
neurons exhibit circadian rhythms in electrical activity and gene expression in 
cultured brain slices as well as in dissociated cell culture. Although discrete SCN 
neurons in culture still display circadian rhythms in electrical activity, they usually 
become desynchronized (Welsh et al., 1995). It is thought that synchronization 
may involve the release of neurotransmitters such as GABA, as well as other 
electrical or chemical signals (Colwell 2000; Liu and Reppert 2000).  
Anatomical studies have shown that the SCN receives input from several 
sources, including the retina, the intergeniculate leaflet (IGL) and the raphe 
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nuclei. Although the IGL and raphe inputs play important roles in modulating the 
SCN clock, SCN clock phase is regulated primarily by the retinal input. 
Interestingly, conventional photoreceptors in retinal rod and cone cells are 
unnecessary for photoentrainment, since mutant mice lacking rods and cones 
are capable of normal photoentrainment (Freedman et al., 1999). These and 
other studies led to the discovery of a third class of photoreceptors that is not 
involved in visual image formation, melanopsins. Melanopsins are expressed in a 
subset of retinal ganglion cells (RGCs). Melanopsin knockout mice show 
attenuated light-induced phase shifting, and fail to show pupil constriction  in 
response to light (Panda et al., 2002; Lucas et al., 2003). Photic signals are 
sensed by melanopsin-containing retinal ganglion cells that synapse onto SCN 
core neurons, where they secrete the neurotransmitter glutamate (Aronson et al., 
1993; Moore et al., 2002). More recently, it has been shown that SCN neurons 
display some transient light adaptation properties, suggesting that input from 
rods and cones can also influence SCN neuronal activity (Drouyer et al., 2007).  
The light-induced glutamate release in the SCN can reset clock phase when 
light occurs during the subjective night, inducing delays in the early night and 
advances in the late night. These responses of the SCN clock to photic stimuli 
can be mimicked by brief application of glutamate in vitro to SCN-containing 
brain slices. SCN neurons express ionotropic AMPA and NMDA receptors, which 
are activated by glutamate (Ebling 1996). Application of NMDA replicates the 
phase-shifting response generated by glutamate application (Ding et al., 1994). 
Conversely, blocking NMDA receptors prevents photic phase shifts (Ding et al., 
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1994). Together, these data show that glutamate transmits light signals from the 
retina to the SCN primarily through activation of NMDA receptors.  
Ca2+ influx through NMDA receptors serves as a second messenger that 
activates various enzymes within the cell, including nitric oxide synthase (NOS). 
Local administration of the NOS inhibitor, L-NAME, in the SCN blocks glutamate-
induced phase shifts (Ding et al., 1994; Weber et al., 1995). Therefore, it is 
hypothesized that after glutamate binds to NMDA receptors, NOS is activated 
and its product, NO, participates in glutamate-induced phase shifts.  
The signaling pathway underlying glutamate-induced phase shifts diverges 
depending on the time of stimulation. In the late night, NO activates guanylate 
cyclase, generating cGMP and activating cGMP-dependent protein kinase 
(PKG). This NO/cGMP/PKG pathway has been shown to induce phase advances 
in vitro (Ding et al., 1998). In the early night, on the other hand, NO is suggested 
to interact with ryanodine receptors (RyR) located on the endoplasmic reticulum 
to induce phase delays (Ding et al., 1998). Pre-treatment of RyR inhibitors to the 
SCN in the early night blocks glutamate-induced phase delays. Those inhibitors 
have no effect on the phase shifts induced during late night (Ding et al., 1998). 
These signaling processes are summarized in Figure 1.  
Although the signal pathways downstream of NO diverge between early and 
late night, they both involve the mitogen-activated protein kinase (MAPK) 
cascade and activation of the gene transcription factor, cAMP response element 
binding protein (CREB), in SCN neurons (Ginty et al., 1993; Ding et al., 1997). 
Binding of CREB to its target, cAMP response element (CRE), on the 
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chromosome triggers transcriptional activation of clock genes. The protein 
products of clock genes make up an autoregulatory negative feedback loop that 
sustains circadian oscillations (see review, Reppert and Weaver, 2001; Hastings 
et al., 2003).  In mammals, the positive component of the feedback loop is the 
heterodimer of Clock and Bmal1 proteins. Binding of the heterodimer to E-box 
motifs in promoter segments stimulates transcription of clock genes. The 
negative component of the loop are the products of three Period (Per) and two 
Cryptochrome (Cry) genes. The Cry and Per proteins also form heterodimers and 
enter the nucleus. During the negative feedback phase, Per/Cry complexes bind 
to and inhibit Clock/Bmal1 activity, thereby down-regulating the transcription of 
clock genes including their own. The ensuing decline in Cry and Per protein 
levels eventually leads to reactivation of Clock/Bmal1-induced clock gene 
transcription and reinitiation of the cycle. 
Rhythmic clock gene expression probably underlies the rhythmic electrical 
activity of SCN neurons (de Jeu et al., 1998; Schaap et al., 1999). It is possible 
that there is direct transcriptional regulation of ion channel proteins or regulatory 
factors affecting channel activity by CLOCK/BMAL1. Clock genes may also 
regulate electrical activity indirectly via clock controlled genes (CCGs), such as 
vasopressin (VP) (Jin et al., 1999). VP appears to augment the magnitude of the 
electrical activity rhythm in the SCN through a receptor-mediated excitation of 
SCN neurons (Mihai et al., 1994; Ingram et al, 1996). 
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Enhancement of Glutamate Signaling by BDNF and PSA-NCAM 
    
NMDA receptor activity is modulated by a number of intracellular and 
extracellular factors. In particular, phosphorylation of various NMDA receptor 
subunit residues can enhance NMDA signaling. For example, a Src-family 
tyrosine kinase, Fyn, is expressed abundantly in neurons and associated with 
NMDA receptors (Salter 1998). The NMDA receptor subunit NR2A is tyrosine-
phosphorylated when coexpressed with Fyn (Tezuka et al. 1999). It has also 
been shown that phosphorylation of NR2B at Tyr-1472 by Fyn is important for 
synaptic plasticity (Nakazawa et al. 2001). Brain-derived neurotrophic factor 
(BDNF) is another potent modulator of synaptic plasticity. Previous studies report 
that BDNF promotes phosphorylation of NR1 and NR2B, which results in an 
enhancement of NMDA receptor activity (Suen et al., 1998; Levine et al. 1998; 
Lin et al. 1998). The blockade of NR2B subunit phosporylation prevents BDNF-
induced enhancement of glutamatergic neurotransmission (Crozier et al. 1999). 
Fyn plays a critical role in BDNF-enhanced NMDA activity, since BDNF-
dependent phosphorylation is abolished in Fyn knockout mice (Xu et al. 2006). 
Fyn has Src homology 2 (SH2) domains, which are supposed to bind to both 
NMDA receptors and the phosphorylated BDNF receptor, TrkB (Iwasaki et al., 
1998). Collectively, these results suggest that BDNF enhances phosphorylation 
of NMDA subunits through activation of Fyn, leading to altered NMDA receptor 
activity and increased synaptic transmission. 
In the hippocampus, BDNF is synthesized as a precursor called proBDNF, 
which is cleaved by plasmin to generate mature BDNF (mBDNF) (Li et al., 2002; 
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Lu, 2003). BDNF and TrkB are co-expressed in the same neurons in the 
hippocampus (Kokaia et al., 1993). BDNF/TrkB signaling facilitates long-term 
potentiation (LTP), a form of long-lasting plasticity observed at synapses in the 
hippocampus and other brain areas, and the proposed cellular mechanism of 
memory formation (Korte et al., 1998). In the hippocampus, binding of BDNF to 
the TrkB receptor leads to phosphorylation of NMDA receptors, which increases 
NMDA-mediated Ca2+ influx (Levine et al., 1998; Crozier et al., 1999). The 
intracellular Ca2+ elevation activates several calcium/calmodulin-dependent 
kinases (Finkbeiner and Greenberg 1997). The TrkB receptor also activates 
several MAP kinases. Activation of both cascades leads to enhanced gene 
transcription (Finkbeiner and Greenberg 1997; Ying et al. 2002).  Hippocampal 
slices from BDNF heterozygous (BDNF+/–) mice fail to exhibit LTP (Korte et al. 
1998).  Application of mBDNF is sufficient to rescue LTP when protein synthesis 
is inhibited, which suggests that mBDNF is a key protein synthesis product for 
LTP expression (Pang et al. 2004). Thus, a model of hippocampal synaptic 
plasticity has emerged whereby BDNF plays an important role in LTP induction.  
Studies suggest that BDNF is also a critical element in photic phase-resetting 
in the SCN. BDNF and TrkB are co-localized in the SCN. BDNF is rhythmically 
expressed in the SCN, with high levels at night and low levels in the day (Liang et 
al., 1998). SCN infusion of the TrkB receptor inhibitor K252a blocks or strongly 
inhibits both the phase-delaying and phase-advancing effects of light during the 
subjective night day (Liang et al., 1998). Heterozygous BDNF mutant mice 
display a damped amplitude of light-induced phase shifts during the subjective 
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night.  Conversely, infusion of exogenous BDNF into the SCN allows light pulses 
to induce large phase advances during the middle of the subjective day, when 
the circadian pacemaker is normally insensitive to photic perturbation. In vitro 
experiments have shown that in the SCN, in order for glutamate to phase-shift 
the clock, BDNF must concurrently activate its TrkB receptors (Liang et al., 1998; 
Liang et al., 2000). BDNF could produce phase shifts through an increase in 
intracellular calcium mediated by NMDA currents.  
Another molecule that can affect glutamate signaling is neural cell adhesion 
molecule (NCAM). NCAM is a homophilic glycoprotein located on the membrane 
of neurons, glia and skeletal muscle (Hoffman et al. 1982; Edelman 1986). 
NCAM has been implicated in processes such as cell-cell adhesion, neurite 
outgrowth, synaptic plasticity and learning and memory (Bonfanti 2006). The 
extracellular domain of NCAM consists of five immunoglobulin-like (Ig) domains 
with different roles in homophilic binding (Kasper et al. 2000). For example, 
polysialic acid (PSA) binds to the fifth Ig domain of NCAM, thereby reducing its 
homophilic binding and cell adhesion properties, which are important in cell 
migration (Ono et al. 1994; Hu, 2000). PSA-NCAM is found in discrete locations 
of the adult brain, including the hippocampus, supraoptic nucleus (SON) and 
SCN. In each of these areas, PSA-NCAM is also thought to play an important 
role in neuronal plasticity. For example, in hippocampal slices, genetic removal of 
NCAM leads to a deficit in LTP, which can be rescued by the BDNF application 
(Muller et al., 2000). These data suggest a link between PSA-NCAM and BDNF 
in the hippocampus.  
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In the SON, the PSA is considered an essential factor for morphological 
plasticity. Lactation and dehydration normally induce withdrawal of astrocytic 
processes around SON neurons, thereby increasing synaptic contacts in the 
SON. Specific enzymatic removal of PSA from NCAM by microinjection of 
endoneuraminidase (endo N) in the SON inhibits these structural changes and 
prevents hormone secretion (Theodosis et al., 1999).  
In the SCN, PSA content in the SCN fluctuates with high levels during the 
day and low levels at night (Glass et al., 2003). Rhythmic fluctuations of PSA 
content have also been shown in vitro (Prosser et al. 2003). Genetic deletion of 
PSA affects circadian rhythm stability (Shen et al., 1997, 2001). Exposure to a 
30-min light pulse during the late night dramatically increases the contents of 
PSA in the SCN within 1 h (Glass et al., 2003). Likewise, in vitro glutamate 
treatment rapidly increases PSA expression in the SCN (Prosser et al., 2003). 
Together, these data suggest that the expression of PSA in the SCN is controlled 
by both the circadian clock and photic input to the clock. 
    As in the hippocampus, evidence suggests a link between BDNF and PSA-
NCAM in the SCN. BDNF actions in the SCN appear to require the PSA form of 
NCAM. When PSA is removed by endo N, BDNF fails to activate its TrkB 
receptor. Under these conditions, glutamate-induced phase shifts are blocked in 
vitro (Prosser et al., 2003). One hypothesis regarding how PSA-NCAM and 
BDNF interact is that the electronegatively-charged PSA may stabilize 
electropositive BDNF and enhance its ability to bind its TrkB receptor (Kiss et al.,  
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2001) The potential interactions between PSA-NCAM and BDNF, and their 
participation in photic phase-resetting are illustrated in Fig. 1. 
 
 
Activation of BDNF by Fibrinolytic Proteins 
 
Tissue-type plasminogen activator (tPA) was originally identified in plasma as a 
secreted serine protease that converts plasminogen to form plasmin, which is 
involved in fibrinolysis. Fibrinolysis is the process where a fibrin clot, the product 
of coagulation, is broken down. Plasmin cleaves fibrin, leading to the production 
of circulating fragments that are cleared by other proteases (Sappino et al., 
1993). Increased tPA activity causes hyperfibrinolysis, or excessive bleeding, 
whereas decreased activity causes hypofibrinolysis, or the increased blood clots. 
In the plasma, tPA activity is inhibited by the protease inhibitor, plasminogen 
activator inhibitor 1 (PAI-1) (Huntington and Carrell 2001). PAI-1 is the principal 
inhibitor of both tPA and urokinase-type plasminogen activator (uPA), and hence 
is an inhibitor of fibrinolysis. It is a member of the serine protease inhibitor 
(serpin) superfamily. PAI-1 is maintained in an active state by interacting with the 
protein, vitronectin (VN) (Mayasundari et al., 2004). VN is a 70kD glycoprotein 
found in blood plasma and the extracellular matrix (ECM) (Preissner 1991; 
Loskutoff et al. 1999). This protein consists of three domains:  The N-terminal 
domain, a central domain and a C-terminal domain.   VN initially was crystallized 
in complex with PAI-1 (Zhou et al., 2003).   The N-terminal domain of VN binds 
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Figure 1.  Model of cellular photic phase resetting in the SCN. Light causes the 
release of glutamate (Glu) from retinal ganglion cells that project to the SCN via 
the retinohypothalamic tract (RHT). Through the mechanisms shown here, 
glutamate alters the transcription of circadian clock genes and shifts the circadian 
clock to an earlier or later phase. Phase-shifting by glutamate requires the 
neurotrophin brain-derived neurotrophic factor (BDNF) activating its receptor 
(TrkB). PSA-NCAM stabilizes BDNF and enhances its ability to bind its TrkB 
receptor. 
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PAI-1 and stabilizes it, hence VN serves to regulate tPA-initiated proteolysis 
(Dupont et al., 2009).  
Another tPA inhibitor, neuroserpin, is found selectively in the brain (Hastings 
et al., 1997; Krueger et al., 1997), suggesting that in addition to modulating 
fibrinolysis in plasma, tPA performs other roles specifically within the nervous 
system. 
The function of tPA is not limited to fibrinolysis. More recently, tPA and its 
associated proteins have been found to participate in a number of non-fibrinolysis 
associated processes within the nervous system. tPA and its substrate, 
plasminogen, are expressed in brain areas such as cortex, hippocampus and 
cerebellum (Basham and Seeds 2001). For example, in the hippocampus, tPA 
was identified as an immediate-early gene induced shortly after LTP (Qian et al. 
1993).  Research on the hippocampus has demonstrated that the tPA-plasmin 
cascade converts proBDNF to mBDNF (Fig 2), which is then capable of 
activating its TrkB receptor and enhancing NMDA receptor-mediated signaling 
(Nicole et al., 2001; Pang et al., 2004). The application of mBDNF to 
hippocampal slices can rescue impaired L-LTP in both tPA-deficient and 
plasminogen-deficient mice.  
tPA enhancement of NMDA receptor signaling can also be plasmin-
independent. It was reported in a neuronal cell culture system that tPA cleaves 
the NR1 subunit at amino acid Arg260, leading to enhanced NMDA receptor 
signaling (Nicole et al., 2001). Mutation of Arg260 abolished tPA-induced NMDA 
activity (Fernandez-Monreal et al., 2004). An interaction between tPA and the 
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NR2B subunit of NMDA has been reported during ethanol withdrawal-induced 
seizures, which are characterized by enhanced glutamatergic signaling (Pawlak 
et al. 2005).  
In addition to its physiological functions, an understanding of the role of tPA 
in pathological situations has also expanded. For example, the tPA-plasmin axis 
has been identified as participating in neuronal degeneration. Injecting the 
excitotoxic glutamate analog, kainate, into the CA1 region of the hippocampus of 
wild-type mice leads to neuronal damage, and this damage is reduced in either 
tPA-deficient or plasminogen deficient mice (Tsirka et al. 1995, Gualandris et al., 
1996). Coinjection of α2-antiplasmin, an endogenous plasmin inhibitor, with 
kainate, also prevents neurodegeneration, supporting the involvement of plasmin 
in this pathological condition. Further investigation identified laminin, a 
component of the ECM, as a substrate of plasmin proteolysis. Laminin cleavage 
combined with kainate excitotoxicity results in neuronal degeneration (Tsirka et 
al. 1997; Chen et al. 2003). tPA is also involved in other CNS pathologies. For 
example, the tPA-plasmin system has been implicated in the degradation of β-
amyloid in Alzheimer disease in both mice and humans (Ledesma et al. 2000; 
Melchor et al. 2003). Diminished tPA-plasmin activity could therefore contribute 
to increased β-amyloid concentration, which in turn, leads to elevation of PAI-1 
(Tucker et al. 2000; Melchor et al. 2003). 
Although first found in the plasma and peripheral organs, respectively, PAI-1 
and VN mRNA are also found in the CNS. PAI-1 mRNA is expressed in the 
cerebral cortex after stoke, and VN mRNA is found in the meninges of the cortex 
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and spinal cord, and in close proximity to brain capillaries during mouse 
development (Seiffert et al., 1995; Ahn et al., 1999). The functions of PAI-1 and 
VN protein in the brain, however, are still largely unexplored.  
 
Recent microarray studies have found that tPA, PAI-1, VN, and plasminogen 
mRNA are also expressed in the SCN (Menger et al., 2005). tPA mRNA 
expression is rhythmic in SCN, with high expression during the late day. PAI-1 
mRNA is also rhythmically expressed, with its highest levels during the early 
night (Menger et al., 2005). mRNA for plasminogen and VN do not show rhythmic 
expression in the SCN (Menger et al., 2005). Because of the strong parallels 
already shown between LTP-associated processes in the hippocampus and 
photic phase-shifting processes in the SCN, we hypothesized that the tPA 
proteolytic pathway may function in the SCN to activate BDNF, thereby 
enhancing glutamate signaling (Fig. 2). Based on this hypothesis, we sought to 
answer a number of key questions: First, is tPA involved in glutamate actions in 
the SCN? If so, is the ability of tPA to modulate glutamate signaling in the SCN 
constant throughout the day and night? Second, do the actions of tPA involve 
plasmin-dependent processes? Third, do VN and PAI-1 inhibit tPA activity in the 
SCN? Fourth, what are the temporal expression patterns of tPA, plasmin and 
BDNF in SCN? Does glutamate modulate their expression? The first three 
questions are addressed in chapter 2, question 4 is addressed in chapter 3.  
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Figure 2. In the hippocampus, tissue-type plasminogen activator (tPA) activates 
BDNF through converting plasminogen to plasmin, which converts proBDNF to 
mature BDNF, which is required for long-term potentiation (LTP). In the plasma, 
tPA is inhibited by plasminogen activator inhibitor-1 (PAI-1), while vitronectin 
binds to and enhances PAI-1 activity. 
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CHAPTER II 
Tissue-type Plasminogen Activator-Plasmin-BDNF Modulate 
Glutamate-induced Phase-shifts of the Mouse Suprachiasmatic 
Circadian Clock in vitro 
(Published in European Journal of Neuroscience, Vol.30, pp.1451-1460, 2009) 
  
Abstract 
 
The mammalian circadian clock in the suprachiasmatic nucleus (SCN) maintains 
environmental synchrony through light signals transmitted by glutamate released 
from retinal ganglion terminals. Brain-derived neurotrophic factor (BDNF) is 
required for light/glutamate to reset the clock. In the hippocampus, BDNF is 
activated by the extracellular protease, plasmin, which is produced from 
plasminogen by tissue-type plasminogen activator (tPA). We provide data 
showing expression of proteins from the plasminogen activation cascade in the 
SCN and their involvement in circadian clock phase-resetting. Early night 
glutamate application to SCN containing brain slices resets the circadian clock. 
Plasminogen activator inhibitor-1 (PAI-1) blocked these shifts in slices from 
wildtype mice but not mice lacking its stabilizing protein, vitronectin (VN). 
Plasmin, but not plasminogen, prevented inhibition by PAI-1. Both plasmin and 
active BDNF reversed 2-antiplasmin inhibition of glutamate-induced shifts. 2-
Antiplasmin decreased the conversion of inactive to active BDNF in the SCN. 
Finally, both tPA and BDNF allowed daytime glutamate-induced phase-resetting. 
Together, these data are the first to demonstrate expression of these proteases 
in the SCN, their involvement in modulating photic phase-shifts, and their 
activation of BDNF in the SCN, a potential ‘gating’ mechanism for photic phase-
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resetting. These data also demonstrate a functional interaction between PAI-1 
and VN in adult brain. Given the usual association of these proteins with the 
extracellular matrix, these data suggest new lines of investigation into the 
locations and processes modulating mammalian circadian clock phase-resetting. 
 
 
Introduction 
 
The mammalian circadian oscillator located in the suprachiasmatic nucleus (SCN) 
regulates daily behavioral and physiological rhythms (Moore & Eichler, 1972; 
Stephan & Zucker, 1972). The SCN clock synchronizes with the environment 
primarily through light signals received by the retina. Light phase-shifts the clock 
during the night through cellular mechanisms not fully understood. Retinal 
stimulation causes glutamate release within the SCN, which activates N-methyl-
daspartate (NMDA) receptors, leading to postsynaptic Ca2+ influx and activation 
of nitric oxide synthase (Ding et al., 1994). Downstream activation of protein 
kinases and transcriptional regulators leads to altered transcription of clock-
associated genes and resetting of core clock mechanisms (Ding et al., 1997; 
Gillette & Tischkau, 1999; Butcher et al., 2003, 2004, 2005; Pizzio et al., 2003; 
Marpegan et al., 2004; Cheng et al., 2006). Brain-derived neurotrophic factor 
(BDNF) and its receptor, TrkB, are also necessary for photic phase-shifts. BDNF 
protein levels fluctuate rhythmically in the SCN with high levels at night, when 
light and glutamate can phase-shift the clock (Liang et al., 1998). Blocking TrkB 
receptors inhibits light- and glutamate-induced phase-shifts (Liang et al., 2000; 
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Michel et al., 2006). Also, light-induced phase shifts are substantially attenuated 
in BDNF+/- mice (Liang et al., 2000). Finally, exogenous BDNF administration 
during the subjective day allows light and glutamate to induce phase-shifts in the 
daytime in vivo and in vitro, respectively (Liang et al., 2000; Michel et al., 2006). 
    These data raise the possibility that BDNF serves to gate photic phaseshifts. 
BDNF and TrkB are also expressed in the hippocampus (Kokaia et al., 1993). In 
the hippocampus, BDNF is synthesized as a precursor, proBDNF, which is 
converted to its mature form (mBDNF) through the tissue-type plasminogen 
activator (tPA)/plasmin system. tPA is an extracellular serine protease that is 
expressed and secreted in the hippocampus in response to glutamate stimulation 
(Shin et al., 2004), and has been implicated in the modulation of synaptic 
plasticity (Horwood et al., 2001; Pang et al., 2004). The specific downstream 
target of tPA proteolysis is the zymogen plasminogen. tPA converts plasminogen 
to its active form, plasmin, through proteolytic cleavage (Plow et al., 1995). 
Plasmin then cleaves proBDNF to form mBDNF (Lee et al., 2001). Plasminogen-/- 
mice exhibit severely impaired long-term potentiation (LTP) in the hippocampus. 
Application of mBDNF but not proBDNF completely rescues LTP in  
plasminogen-/- mice (Pang et al., 2004). 
    In plasma, tPA cleavage of plasminogen is countered by the serine protease 
inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1; Huntington & Carrell, 
2001). PAI-1 is maintained in its active state by binding with vitronectin (VN; 
Podor et al., 2000a, b; Minor & Peterson, 2002; Mayasundari et al., 2004). 
Functional interactions between PAI-1 and VN in the adult brain have not been 
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investigated. Microarray studies have found that VN, PAI-1, tPA and 
plasminogen mRNA are expressed in the SCN (Panda et al., 2002; Menger et al., 
2005), with tPA and PAI-1 mRNA showing rhythmic expression (Panda et al., 
2002; Menger et al., 2005). Based on these data, we investigated whether tPA 
and plasmin modulate glutamate-induced phase-shifts in the SCN in a PAI-1/VN-
dependent fashion. 
 
 
Materials and methods 
 
Brain slice preparation 
 
Coronal brain slices (500u) containing the SCN were prepared during the early 
subjective day from adult male (> 8 weeks old) C57Bl/J6 (Harlan Laboratories) 
and VN knockout (VN-/-) mice housed in a 12: 12 h light: dark cycle (VN-/- mice 
were generated from C57Bl/J6 mice and kindly provided by Dr Ginsburg at the 
University of Michigan). Mice were killed by decapitation. The slices were 
maintained at the interface of a Hatton-style brain slice chamber continuously 
perfused at 37°C with oxygenated (95% O2/ 5% CO2) Earle’s balanced salt 
solution supplemented with glucose, bicarbonate and gentamicin. The pH was 
adjusted to 7.4 (Prosser, 2003). One mouse was used for each experiment, with 
replicate experiments performed on brain slices from different mice. All 
experimental protocols were approved by the University of Tennessee Knoxville 
Institutional Animal Care and Use Committee. 
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Drug treatments 
 
All treatments were bath-applied on the first day in vitro. To apply the treatments, 
perfusion of the normal medium was stopped and the medium in the chamber 
was replaced with medium containing the appropriate compounds. Glutamate 
application was for 10 min, beginning at Zeitgeber time 16 (ZT16, where ZT0 
corresponds to lights on and ZT12 corresponds to lights off in the donor animal 
colony). In experiments involving compounds other than glutamate, the slices 
were pre-treated with the other substances alone for 30 min (ZT15.5-16.0), and 
then were co-treated with glutamate for 10 min (ZT16.0-16.17). In additional 
experiments, the compounds other than glutamate were applied alone for 40 min 
(ZT15.5-16.17). At the end of the treatments, the normal medium was 
reintroduced into the slice chamber and perfusion was resumed. 
Single-unit recording and data analysis 
 
Single-unit recordings were obtained on day 2 in vitro using methods described 
previously (Prosser, 1998, 2003). Briefly, spontaneous activity of single SCN 
neurons was recorded extracellularly using glass capillary microelectrodes filled 
with 3 M NaCl. Individual neurons were recorded for 5 min, with four-seven cells 
being recorded each hour. The data were later analysed using a DataWave 
system (Berthoud, CO, USA) to determine the average firing rates. The individual 
firing rates were then used to calculate 2-h running averages, lagged by 1 h, to 
obtain a measure of population neuronal activity. The time of peak neuronal 
activity was assessed visually by estimating, to the nearest quarter hour, the time 
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of symmetrically highest activity. As is the accepted standard for these types of 
experiments (Prosser et al., 1994; Ding et al., 1997, 1998; Prosser, 2003; Soscia 
& Harrington, 2004; Tischkau et al., 2004; Yannielli & Harrington, 2004), phase-
shifts were calculated as the difference in time-of-peak between untreated 
(control) slices and drug-treated slices. Statistical analyses were performed using 
Sigmastat (San Jose, CA, USA). One-way anova was used to test for significant 
differences between treatment and control experiments, followed by Dunnett’s 
test for post hoc comparisons. Significance was set at p < 0.05. 
 
Western blots 
 
To assess in vivo protein expression, SCN tissue was dissected from mouse 
brains and immediately frozen for later Western blot assay. In all other protein 
assay experiments brain slices containing the SCN and underlying optic chiasm 
were prepared and maintained undisturbed in the slice chamber for harvesting 
later. At the appropriate time, the tissue was then removed and homogenized in 
ice-chilled HEPES-based extraction buffer containing a protease inhibitor cocktail 
(1 mm phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin, 15 mg/mL leupeptin, 
10 mg/mL pepstatin). For the BDNF immunoblot, tissue was prepared in Tris-
based denaturing extraction buffer [4 M urea, 0.02 M dithiothreitol, 0.05 M Tris, 
pH 7.4, 2% sodium dodecyl sulfate (SDS)]. The tissue extract sample was 
separated into aliquots and stored at -80°C. Protein content of the extract was 
determined by the bicinchoninic acid method (BCA; Pierce). Tissue samples 
were mixed with loading buffer (pH 6.8 Tris, SDS, bromophenol blue, glycerol), 
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and subjected to SDS–polyacrylamide gel electrophoresis (PAGE). Proteins were 
electrotransferred onto nitrocellulose membranes, which were then incubated 
with blocking buffer [10% solution of non-fat dry milk in phosphate-buffered saline 
with Tris (PBST)]. The membranes were probed with primary antibodies diluted 
in a 2.0% solution of non-fat dry milk in PBST, followed by goat anti-rabbit 
horseradish peroxidase-conjugated secondary antibody at appropriate dilutions 
in the same buffer. Signals were revealed by enzyme-catalysed 
chemiluminescence (Pierce, IL, USA). The amount of protein loaded in each lane 
was assessed by probing for actin, so all protein expression is reported as levels 
relative to actin. Control experiments included running parallel lanes loaded with 
the corresponding native proteins (positive controls), and probing membranes 
with primary antibodies pre-incubated with the native protein to test for cross-
reactivity and to establish the specificity of the antibody samples. Rabbit anti-
plasminogen, anti-tPA, anti-PAI-1 and anti-VN antibodies were obtained from 
Molecular Innovations (Detroit, MI, USA), and rabbit anti-actin and anti-BDNF 
antibodies were from Santa Cruz Biochemicals (Santa Cruz, CA, USA). 
 
 
 
Results 
 
Expression of fibrinolytic proteins and BDNF in the SCN 
 
Although microarray studies have shown gene expression for tPA, VN, PAI-1 and 
plasminogen in the SCN (Panda et al., 2002; Menger et al., 2005), no studies 
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have focused on expression of the respective proteins. Therefore, in these 
experiments we used Western blot procedures to assess which of these proteins 
are expressed in the SCN at ZT16, when light/glutamate can reset the SCN clock. 
For these experiments we prepared slices that were smaller than those used in 
the electrophysiology experiments, so that they contained only the SCN and 
underlying optic chiasm. Individual slices were maintained in the slice chamber 
until ZT16, when they were removed and subjected to homogenization and 
protein quantification.  
As shown in Fig. 3A, anti-PAI-1 antibody identified an approximately 45-kD 
band in SCN samples from wild-type brain slices. Immunoreactive bands of VN 
and PAI-1 were slightly larger than their positive controls, presumably due to 
glycosylation (Uchibori-Iwaki et al., 2000; Brogren et al., 2008). We detected tPA 
protein in SCN samples from both VN-/- knockout (data not shown) and wild-type 
mice as an approximately 60-kD band that matched the positive control. As 
documented previously (Zheng et al., 1995), we found no VN protein in SCN 
tissue from VN-/- mice (data not shown). We identified plasminogen as an 
approximately 90-kD band that matched the positive control, whereas plasmin 
was seen as approximately 50-kD and approximately 40-kD bands under 
reducing conditions. Mature BDNF protein was consistently detected by Western 
blot analysis of pooled samples of three SCN slices as a prominent 
immunoreactive band with a molecular size of 15 kD (Fig. 3B). We also observed 
bands of approximately 25 kD and approximately 37 kD, which correspond to 
proBDNF (Mowla et al., 2001; Pollak et al., 2005). To verify antibody specificity, 
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anti-BDNF, anti-PAI-1, anti-tPA and anti-plasminogen primary antibodies were 
incubated with and without corresponding purified proteins in solution to test for 
specific competition in the Western blot.  
In a second set of experiments, SCN tissue was placed in extraction buffer for 
Western blot analysis immediately after dissection in order to assess in vivo 
protein expression. The results (Fig. 3C) demonstrated that the fibrinolytic 
proteins (tPA, PAI-1, plasminogen, VN) are all expressed in the SCN in vivo.  
In a final set of experiments assaying protein expression, we prepared SCN 
brain slices and maintained them in vitro for 3, 6 and 9 h prior to placing them in 
extraction buffer. Western blot analysis for tPA protein in these slices 
demonstrated no pronounced trauma-induced changes in the expression of tPA 
protein (Fig. 3D). Glutamate-induced phase delays are blocked by PAI-1. 
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm 
with a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal 
activity in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These 
results are consistent with previous work (Prosser, 2003). Glutamate (1 mM) 
applied to brain slices in the early subjective night for 10 min (ZT16-16.17) 
delayed the SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak 
occurred at ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. 
These data are consistent with previous studies (Ding et al., 1994; Prosser et al., 
2003). Pre-treating brain slices for 30 min prior to glutamate treatment with the 
tPA inhibitor, PAI-1, blocked the glutamate-induced phase-shifts (mean phase-
shift =-0.38 ± 0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, 
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with an ED50 (dosage of drug that produces 50% of the maximum effect) of about 
0.6 nM (Fig. 5). This corresponds to its concentration in the serum (Devy et al., 
2002). From this value, it is clear that tissue injury in our SCN slice preparation 
procedure did not induce a sustained release of tPA. The inhibition by PAI-1 was 
prevented by coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the 
resulting phase-shift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied 
alone, PAI-1 and tPA each had no effect on the phase of the neuronal activity 
rhythm. The effects of all these treatments are summarized in Fig. 5. 
Glutamate-induced phase delays are blocked by PAI-1 
 
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with 
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity 
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results 
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to 
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the 
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at 
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are 
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pre-
treating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor, 
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ± 
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50 
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig. 
5). This corresponds to its concentration in the serum (Devy et al., 2002). From 
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this value, it is clear that tissue injury in our SCN slice preparation procedure did 
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by 
coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phase-
shift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA 
each had no effect on the phase of the neuronal activity rhythm. The effects of all 
these treatments are summarized in Fig. 5. 
Glutamate-induced phase delays are blocked by PAI-1 
 
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with 
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity 
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results 
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to 
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the 
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at 
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are 
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pre-
treating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor, 
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ± 
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50 
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig. 
5). This corresponds to its concentration in the serum (Devy et al., 2002). From 
this value, it is clear that tissue injury in our SCN slice preparation procedure did 
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by 
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coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phase- 
shift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA 
each had no effect on the phase of the neuronal activity rhythm. The effects of all 
these treatments are summarized in Fig. 5. 
Glutamate-induced phase delays are blocked by PAI-1 
 
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with 
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity 
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results 
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to 
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the 
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at 
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are 
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pre-
treating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor, 
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ± 
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50 
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig. 
5). This corresponds to its concentration in the serum (Devy et al., 2002). From 
this value, it is clear that tissue injury in our SCN slice preparation procedure did 
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by 
coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phase-
shift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA 
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Figure 3. Expression of vitronectin (VN), plasminogen activator inhibitor-1 (PAI-
1), plasminogen, plasmin, tissue-type plasminogen activator (tPA) and brain-
derived neurotrophic factor (BDNF) in the SCN. (A–C) Samples maintained in 
vitro for 12–14 h, until ZT16. (A) Lane 1 shows native protein controls; lane 2 
shows SCN protein samples. (B) Lane 1 shows BDNF protein control; lanes 2 
and 3 shows SCN protein samples, with lane 3 a longer-duration exposure of the 
same blot shown in lane 2. (C) Lane 1 shows native protein controls; lane 2 
shows SCN protein samples placed in extraction buffer immediately after 
dissection. Westerns shown here were run under non-reducing conditions, so 
plasmin bands do not separate from plasminogen. (D) Histogram showing tPA 
levels (relative to actin) at different times after slice preparation (n = 3 for each 
time point). Data are normalized to samples obtained after 9 h in vitro.  
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each had no effect on the phase of the neuronal activity rhythm. The effects of all 
these treatments are summarized in Fig. 5. 
Plasmin activation of BDNF is necessary for glutamate-induced phase 
delays 
 
Next we investigated whether the actions of tPA in the SCN result directly from 
the conversion of plasminogen to plasmin. If the effects are specific and require 
the plasminogen activation cascade to produce plasmin, then co-application of 
active plasmin should overcome the effect of blocking tPA activity. Therefore, in 
the next set of experiments, we co-applied either plasmin (40 ug/mL) or 
plasminogen (40 ug/mL) with PAI-1 beginning 30 min prior to glutamate 
administration. Glutamate-induced phase-shifts were restored by plasmin (mean 
shift = -3.69 ± 0.47 h, n = 3), whereas co-application of plasminogen did not 
prevent PAI-1 inhibition (mean phaseshift = -0.04 ± 0.29 h, n = 5; Fig. 6). 
Plasminogen and plasmin alone had no effect.  
    To further examine the requirement for plasmin in glutamate phaseshifts, we 
co-applied the endogenous plasmin antagonist, 2-antiplasmin, along with 
glutamate at ZT16. Consistent with the previous results, 2-antiplasmin also 
inhibited glutamate-induced phase-shifts (Fig. 6). This inhibition was dose-
dependent (Fig. 6), with an ED50 estimated at 10 nM. Finally, the inhibition by 2-
antiplasmin was prevented by co-application of excess plasmin (80 ug/mL; mean 
phase-shift = -2.19 ± 0.47 h, n = 3; Fig. 6). In control experiments, 2-antiplasmin 
had no effect on the phase of the neuronal activity rhythm (Fig. 6). 
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Figure 4. Glutamate-induced phase-shifts of neuronal activity are blocked by 
plasminogen activator inhibitor-1 (PAI-1). Shown here are the 2-h means ± SEM 
of spontaneous neuronal activity recorded in single experiments. (A) Control 
experiment shows peak activity at ZT6. (B) Glutamate (1 mm) treatment at ZT16 
induces a nearly 3-h phase delay. (C) PAI-1 (0.5 um) treatment beginning at 
ZT15.5 blocks the glutamate-induced phase-shift. (D) Co-application of tissue-
type plasminogen activator (tPA; 1 ug/mL) with PAI-1 prevents the PAI-1 
inhibition. Vertical bars show the time of drug treatment. The dotted line shows 
the mean time-of-peak in control experiments. Horizontal black bars represent 
lights-off in the animal colony. 
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Figure 5. Modulation of glutamate-induced phase-shifts by tissue-type 
plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). PAI-1 
blocks glutamate-induced phase delays in a dose-dependent fashion. (A) Shown 
are the mean (± SEM) phase-shifts induced by the treatments indicated. PAI-1 (5 
nm) blocks glutamate-induced phase delays, while excess tPA (1 ug/mL) 
prevents this inhibition. In control experiments, PAI-1 and tPA applied alone or 
together had no effect on the phase of neuronal activity. One-way ANOVA 
indicated a significant effect of the treatments (F6,18=14.13). *Phase delays 
significantly different from control (no treatment) slices based on post hoc 
(Dunnett’s) test (p<0.001). (B) Mean (± SEM) phase-shifts induced by glutamate 
applied with varying concentrations of PAI-1. Delays are plotted as negative 
values. ZT, Zeitgeber time.  
 
 
 
 
 
 
 
 
 
  32 
Plasmin activation of BDNF is necessary for glutamate-induced phase 
delays 
 
Next we investigated whether the actions of tPA in the SCN result directly from 
the conversion of plasminogen to plasmin. If the effects are specific and require 
the plasminogen activation cascade to produce plasmin, then co-application of 
active plasmin should overcome the effect of blocking tPA activity. Therefore, in 
the next set of experiments, we co-applied either plasmin (40 ug/mL) or 
plasminogen (40 ug/mL) with PAI-1 beginning 30 min prior to glutamate 
administration. Glutamate-induced phase-shifts were restored by plasmin (mean 
shift = -3.69 ± 0.47 h, n = 3), whereas co-application of plasminogen did not 
prevent PAI-1 inhibition (mean phaseshift = -0.04 ± 0.29 h, n = 5; Fig. 6). 
Plasminogen and plasmin alone had no effect.  
    To further examine the requirement for plasmin in glutamate phaseshifts, we 
co-applied the endogenous plasmin antagonist, 2-antiplasmin, along with 
glutamate at ZT16. Consistent with the previous results, 2-antiplasmin also 
inhibited glutamate-induced phase-shifts (Fig. 6). This inhibition was dose-
dependent (Fig. 6), with an ED50 estimated at 10 nM. Finally, the inhibition by 2-
antiplasmin was prevented by co-application of excess plasmin (80 ug/mL; mean 
phase-shift = -2.19 ± 0.47 h, n = 3; Fig. 6). In control experiments, 2-antiplasmin 
had no effect on the phase of the neuronal activity rhythm (Fig. 6). 
    In the next set of experiments, we investigated whether plasmin functions in 
the SCN to activate BDNF. For these experiments we applied exogenous 
mBDNF (200 ng/mL), beginning 30 min prior to co-application of glutamate and 
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2-antiplasmin. mBDNF pre-treatment fully restored the glutamate-induced 
phase-shifts that were inhibited by 2-antiplasmin (mean phase-shift = -2.11 ± 
0.41 h, n = 3; Fig. 6), while mBDNF treatment alone had no effect (mean phase-
shift = 0.06 ± 0.00 h, n = 2; Fig. 6). These data support the conclusion that 
plasmin acts in the SCN to convert proBDNF to mBDNF. 
Finally, we investigated whether 2-antiplasmin treatment alters the production 
of mBDNF in the SCN. SCN brain slices were left untreated, treated with 
glutamate, or treated with glutamate + 2-antiplasmin for 10 min at ZT16. At the 
end of this time slices were removed from the slice chamber and processed for 
Western blot analysis. The results (Fig. 6) indicate that glutamate treatment did 
not affect the level of mBDNF in the SCN, but glutamate + 2-antiplasmin 
treatment significantly decreased the amount of mBDNF in the SCN. These data 
are consistent with the hypothesis that plasmin functions in the SCN to activate 
BDNF.                
Involvement of tPA-plasmin-BDNF in late subjective night phase advances 
 
The experiments described above were all conducted during the early 
subjective night, investigating glutamate-induced phase delays. Because there 
are significant differences in the phase-resetting mechanisms associated with 
photic phase delays and phase advances, it is important to determine whether 
these proteins also modulate glutamate-induced phase advances. Glutamate 
application alone at ZT23 induced 3-h phase advances, as shown previously 
(Ding et al., 1994; Prosser et al., 2003). As seen with early night drug treatments, 
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Figure 6. Plasmin activity is necessary for glutamate-induced phase-shifts. (A) 
Shown are the mean (± SEM) phase-shifts induced by the treatments indicated. 
Exogenous plasmin (40 ug/mL), but not plasminogen (40 ug/mL), prevents 
plasminogen activator inhibitor-1 (PAI-1) inhibition of glutamate-induced phase-
shifts. The endogenous plasmin inhibitor, 2-antiplasmin (0.05 uM), inhibits 
glutamate-induced phase-shifts, and this inhibition is reversed by either excess 
plasmin (80 ug/mL) or (m)brain-derived neurotrophic factor (BDNF; 200 ng/mL). 
In control experiments, plasmin (40 lg/mL), plasminogen, a2-antiplasmin and 
mBDNF in isolation had no effects on the phase of neuronal activity. One-way 
anova indicated a significant effect of the treatments (F10,37 = 20.4). *Phase 
delays significantly different from control (no treatment) slices based on post hoc 
(Dunnett’s) test (p<0.001). See Fig. 5 for details. (B) 2-Antiplasmin dose-
dependently blocks glutamate-induced phase delays. Shown are the mean (± 
SEM) phase-shifts induced by glutamate applied with varying concentrations of 
2-antiplasmin. Delays are plotted as negative values. (C) Glutamate treatment 
did not alter mBDNF protein expression in the SCN, but glutamate + 2-
antiplasmin treatment significantly decreased the amount of mBDNF in the SCN 
(p= 0.01). ZT, Zeitgeber time 
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co-application of either PAI-1 or 2-antiplasmin blocked the glutamate-induced 
phase advances. Furthermore, although BDNF treatment alone at ZT23 had no 
effect, BDNF was able to prevent the inhibition induced by 2-antiplasmin (Fig. 7). 
 
 
BDNF acts as a gating molecule for photic phase-resetting 
 
The data thus far indicate that mBDNF is important for glutamate-induced phase-
resetting. These data are consistent with previous studies showing that BDNF 
protein levels are high in the SCN during the night, when light phase-shifts the 
clock (Liang et al., 1998). Furthermore, blocking BDNF activity with K252a 
prevents photic phase-resetting (Liang et al., 2000; Michel et al., 2006), while 
continuous infusion of BDNF allows photic phase-shifts during the day (Liang et 
al., 2000). To further explore the potential role of mBDNF as a gating molecule 
for photic phase-resetting, we initiated a series of experiments investigating the 
effects of daytime BDNF signaling in the SCN. 
 
    Control slices that received treatments of either 10 min glutamate at ZT6 or 40 
min mBDNF (100 ng/mL) starting at ZT5.5 did not show significant phase-
resetting responses (-0.18 ± 0.0 h and -0.27 ± 0.4 h, respectively). However, 
slices treated with glutamate+ BDNF underwent phase advances averaging 3.32 
± 0.3 h. These daytime phase advances were blocked by co-treatment with the 
TrkB antagonist, K252a (mean phase advance = 0.07 ± 0.2 h, n = 3). K252a 
treatment alone during the subjective day had no effect (Fig. 8). 
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Figure 7. tPA-plasmin-brain-derived neurotrophic factor (BDNF) modulation of 
late-night phase advances by glutamate. Shown are the mean phase-shifts 
induced by treatments applied to SCN brain slices at Zeitgeber time (ZT) 23. 
Glutamate induced a 3-h phase advance, which was inhibited by either 
plasminogen activator inhibitor-1 (PAI-1) or 2-antiplasmin treatment. Co-
application of BDNF prevented the inhibition by 2-antiplasmin, while it had no 
effect when applied alone. One-way ANOVA indicated a significant effect of the 
treatments (F5,17 = 53.19). *Phase-shifts significantly different from control (no 
treatment) slices based on post hoc (Dunnett’s) test (p< 0.001).  
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To investigate whether daytime BDNF availability is regulated by tPA, we also 
investigated whether glutamate induces daytime phase advances when applied 
together with tPA. As shown in Fig. 8, co-treatment of SCN brain slices with 
glutamate + tPA at ZT6 also induced a phase advance. These data suggest that 
the amount of active tPA in the SCN is limited in the daytime. 
 
VN is necessary for PAI-1 actions in the SCN 
 
Having shown that PAI-1 can block tPA activity in the SCN, we next 
investigated whether VN is needed for sustained PAI-1 activity in the SCN. In the 
plasma, VN acts as a cofactor, binding to PAI-1 and maintaining it in its active 
form (Podor et al., 2000b; Minor & Peterson, 2002). If this protein interaction 
occurs in the SCN, then PAI-1 inhibition of glutamate-induced phase-shifts 
should be impaired in VN knockout (VN-/-) mice. Therefore, we investigated 
glutamate-induced phase-shifts in brain slices prepared from VN-/- mice. First, we 
conducted control experiments for VN-/- mice. In vitro SCN neuronal activity from  
VN-/- mice exhibited a circadian rhythm with a peak during mid-day (mean time of 
peak = ZT6.75 ± 0.30, n = 3; Fig. 9). This time-of-peak is not significantly 
different from that observed in wild-type SCN brain slices. Although a detailed 
assessment of photic entrainment in the VN-/- mice is beyond the scope of this 
study, the fact that the phase of the SCN neuronal activity rhythm seen in vitro 
matches that seen in brain slices from wild-type mice suggests there is no major 
detriment in photic entrainment in these mice. This result would be expected in 
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Figure 8. Brain-derived neurotrophic factor (BDNF) gates glutamate-induced 
phase-shifts. Shown are the mean phase-shifts induced by treatments applied to 
SCN brain slices during the subjective day. Glutamate and BDNF treatments 
applied individually had no effect, while together they induced a 3-h phase 
advance. The TrkB antagonist, K252a, prevented this phase-shift. Co-treatment 
with glutamate and tissue-type plasminogen activator (tPA) also phase advanced 
the neuronal activity rhythm. One-way ANOVA indicated a significant effect of the 
treatments (F6,19 = 42.1). *Phase-shifts significantly different from control (no 
treatment) slices based on post hoc (Dunnett’s) test (p< 0.001). ZT, Zeitgeber 
time.  
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the absence of VN, a cofactor and stabilizer of PAI-1, which appears to be an 
inhibitor of entrainment processes. To maintain consistency in the analyses used 
throughout this study, therefore, we continued to calculate phase-shifts relative to 
the mean time-of-peak in the SCN from wild-type mice. Glutamate-induced 
phase delays in VN-/- SCN brain slices were the same magnitude as those seen 
in wild-type brain slices (mean phase shift= -2.44 ± 0.35 h, n = 2; Fig. 9). Next, 
we applied PAI-1 and glutamate in the same manner as used in our previous 
experiments. Unlike the results obtained using wild-type tissue, PAI-1 did not 
block glutamate-induced phase-shifts in SCN brain slices prepared from VN-/- 
mice (mean phase-shift = -2.63 ± 0.25 h, n = 4; Fig. 9).  
To confirm that the tPA-plasminogen-plasmin pathway is functional in the SCN 
of VN-/- mice, we co-applied 2-antiplasmin with glutamate to SCN brain slices 
from VN-/- mice. As seen with wild-type tissue, 2-antiplasmin inhibited glutamate-
induced phase-shifts (mean phase shift = -0.42 ± 0.10 h, n = 3; Fig. 9). In control 
experiments on VN-/- SCN tissue, PAI-1 alone had no effect (mean phase shift = -
0.67 ± 0.11 h, n = 3), while 2-antiplasmin induced a small phase advance (0.75 
± 0.43 h, n = 3; Fig. 9). 
 
Discussion 
 
The results presented here are the first to demonstrate expression of tPA and its 
associated proteins in the SCN, and to begin elucidating their functions 
associated with the SCN circadian clock. We show that tPA-dependent 
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generation of plasmin is necessary for glutamate-induced phase-shifts, and tPA 
activity in the SCN is inhibited by PAI-1 paired with its cofactor, VN. These data 
significantly expand the known functions of these proteins within the nervous 
system, and demonstrate a novel and unexpected regulatory process modulating 
photic-resetting of the mammalian circadian system.  
      Our initial experiments focused on tPA. A role for tPA in enhancing glutamate 
signaling in the SCN is consistent with studies showing that tPA enhances 
glutamatergic excitotoxicity that is associated with stroke-related brain injury 
(Dietzmann et al., 2000; Yepes et al., 2002; Kumada et al., 2004). In the SCN, 
however, tPA is involved as a component in a normal regulatory mechanism 
rather than a pathological process. In this regard, tPA actions in the SCN are 
similar to those in the hippocampus, where the protease modulates glutamate-
dependent memory processes in a normal physiological context (Pang et al., 
2004). Our data do not address the issue of whether urokinase plasminogen 
activator (uPA) is involved in these processes. uPA is expressed in the brain, 
although its expression in the adult brain appears to be more  associated with 
tumor growth than with normal processes (Zhang et al., 2005). Future 
experiments using tPA and uPA knockout mice could explore the relative 
importance of these two plasminogen activators in regulating plasmin levels in 
the SCN. 
    PAI-1 is mainly produced by endothelial cells lining blood vessels, where it 
decreases blood clot lysis by inhibiting tPA (Reilly &Hutzelmann, 1992; Fay et al., 
1994). Its expression and actions in the brain, however, are not well understood. 
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Figure 9. Vitronectin (VN) is needed for plasminogen activator inhibitor-1 (PAI-1) 
to block glutamate-induced phase-shifts. Shown are the mean phase-shifts 
generated by application of the treatments indicated to SCN brain slices obtained 
from VN-/- mice (calculated relative to the time-of-peak in wild-type SCN controls). 
The time of peak neuronal activity in VN-/- SCN brain slices is not significantly 
different from that of controls. Glutamate (1 mM) induces normal phase-shifts, 
but PAI-1 (0.5 uM) does not block these phase-shifts in SCN brain slices 
prepared from VN-/- mice. Conversely, 2-antiplasmin (0.05 uM) continues to 
block glutamate-induced phase-shifts in these slices. 2-Antiplasmin alone 
induced a small but significant phase advance. One-way ANOVA indicated a 
significant effect of the treatments (F6,21= 38.65). *Phaseshifts significantly 
different from control (no treatment) slices based on post hoc (Dunnett’s) test (p 
< 0.05). ZT, Zeitgeber time.  
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PAI-1 is expressed in the brain following trauma (Ahn et al., 1999; Dietzmann et 
al., 2000; Salles & Strickland, 2002), and expression has also been reported in 
some areas, including the hypothalamus, under non-traumatized conditions (Hino 
et al., 2001). Rhythmic expression of PAI-1 mRNA has been detected in the SCN 
using microarrays, with peak expression in the early subjective night. Our data 
are consistent with these findings, in that we detect PAI-1 protein in the SCN in 
our brain slices at ZT16. It will be important to determine whether similar levels of 
PAI-1 protein are seen in the SCN in vivo, and if the expression is rhythmic. 
Regardless of whether PAI-1 expression varies across the circadian cycle, its 
presence here indicates that tPA activity in the SCN is under inhibitory control. 
    PAI-1 also has been shown to inhibit glutamate-associated synaptic plasticity 
in cultured hippocampal neurons (Neuhoff et al., 1999). While this likely involves 
inhibition of tPA activity, the mechanism for this effect has not been delineated. 
Thus, our results are the first to demonstrate a functional interaction between 
PAI-1 and tPA in the SCN, where they play a critical role in modulating photic 
phaseresetting of the SCN clock. 
    Previous work indicates that tPA can act through both plasmin dependent and 
-independent mechanisms (Arroyo De Prada et al., 2002; Yepes et al., 2003; 
Fernandez-Monreal et al., 2004; Matys et al., 2004; Kumada et al., 2005; Pawlak 
et al., 2005). Therefore, we designed our experiments to explicitly test for a role 
of the plasminogen activation cascade in the SCN. Our data demonstrate that 
tPA acts in the SCN through conversion of plasminogen to plasmin. First, we 
show that plasminogen protein is expressed in the SCN. Second, co-application 
  44 
of plasmin with PAI-1 prevents PAI-1 inhibition of glutamate-induced phase-shifts, 
while co-application of plasminogen does not. Third, co-application of 2-
antiplasmin inhibits glutamate-induced phase-shifts. The inhibition by 2-
antiplasmin is dose-dependent, with an ED50 about 10 nM, corresponding to its 
concentration in the plasma (Collen & Wiman, 1978; Cederholm- Williams, 1981). 
These results are consistent with studies in the hippocampus showing that 
plasmin rescues a LTP deficit seen in tissue obtained from tPA-/- mice, while 
application of plasminogen to tPA-/- slices has no effect (Pang et al., 2004). 
Furthermore, this work establishes a role for plasmin in BDNF activation in the 
SCN that is similar to the interaction between plasmin and BDNF that has been 
demonstrated in the hippocampus. In vitro experiments in the hippocampus show 
that plasmin cleaves proBDNF to generate mBDNF (Pang et al., 2004). Pang et 
al. (2004) also report that treating plasminogen-/- slices with mBDNF reinstates 
their capacity to generate LTP, whereas treating BDNF+/- slices with plasmin 
does not rescue LTP. This work further documented that neither tPA nor 
plasminogen alone is capable of cleaving proBDNF to form mBDNF. Treating 
slices with tPA and plasminogen, however, is as effective as plasmin in 
generating mBDNF. These findings indicate that in the hippocampus, tPA affects 
proBDNF cleavage indirectly by activating plasmin. In a similar fashion, our 
experiments show that exogenous mBDNF restores the glutamate-induced 
phase-shifts that are inhibited by 2-antiplasmin. Importantly, we also find that 2-
antiplasmin treatment decreases mBDNF levels in the SCN.  
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Several studies have demonstrated that BDNF is necessary for photic phase-
shifts of the SCN circadian clock. BDNF+/- mice have reduced light-induced 
phase-shifts, and blocking TrkB receptors prevents light- and glutamate-induced 
phase-shifts in vivo and in vitro, respectively (Liang et al., 2000; Michel et al., 
2006). There are circadian rhythms in BDNF protein and mRNA expression in the 
SCN, with peak levels at night, when glutamate and light are capable of phase-
shifting the clock (Liang et al., 1998, 2000). These studies did not establish, 
however, whether the rhythmic protein corresponds to proBDNF, mBDNF, or a 
combination of both. It is also not clear whether there is a rhythm in BDNF 
release in the SCN. In the hippocampus, most proBDNF appears to be converted 
to mBDNF extracellularly (Lee et al., 2001). Our data showing a decrease in 
mBDNF levels after 2-antiplasmin treatment suggest that, as in the 
hippocampus, proBDNF is converted to mBDNF extracellularly through 
proteolytic cleavage by plasmin. 
    Our data further support the idea that mBDNF acts as a gating molecule for 
photic phase-resetting. Similar to in vivo results using chronic BDNF infusions, 
we show that acute application of BDNF to SCN brain slices allows glutamate to 
induce TrkB-dependent phase shifts in the subjective day. These data suggest 
that all the cellular components necessary for glutamate-induced phase-shifts 
downstream from mBDNF are available throughout the 24-h cycle. Adding 
mBDNF in the day allows glutamate to generate phase-shifts, while preventing 
mBDNF production at night prevents the phase-shifts. Our finding that co-
treatment with tPA and glutamate is also able to phase advance the SCN 
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circadian clock suggests that there may be sufficient pro-BDNF available in the 
SCN during the daytime, but that the amount of active tPA is limited. 
    Because of the close association of VN and PAI-1 in many physiological 
scenarios, we investigated the role of VN related to the plasminogen cascade 
and its effects in the SCN. Very little is known about the actions of VN in the adult 
brain. VN is primarily produced in the liver (Seiffert et al., 1994; Seiffert, 1997); 
however, VN mRNA expression has also been shown in the brain, e.g. in the 
meninges and in close proximity to brain capillaries (Seiffert et al., 1996). Our 
results extend the current understanding to indicate that VN protein is found in 
the SCN. These results are consistent with previous microarray data showing VN 
mRNA expression in SCN2.2 cells, a line of immortalized SCN cells derived from 
rats (Menger et al., 2005). 
    In the periphery, VN is usually associated with the extracellular matrix, where it 
binds to multiple proteins. Through interactions with integrins, VN modulates cell 
migration and growth (Isahara & Yamamoto, 1995; Kjoller et al., 1997). Through 
its interaction with PAI-1, VN maintains PAI-1 in its active form (Podor et al., 
2000a,b; Minor & Peterson, 2002), such that it can effectively inhibit tPA. The fact 
that SCN electrical activity rhythms in tissue from VN-/- mice peak at the normal 
time in vitro indicates that the SCN clock in these mice does not exhibit marked 
deficits in photic entrainment. Together, these data are consistent with VN acting 
in the SCN to stabilize and/or localize PAI-1. Disrupting the interaction of VN with 
PAI-1 thus appears to decrease the inhibitory regulation of tPA, which if anything 
should enhance SCN responsiveness to photic-entraining signals. The VN ⁄ PAI-1 
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interaction appears to play an active role in the SCN, as PAI-1 does not block 
glutamate-induced phase-shifts in SCN brain slices obtained from VN-/- mice. 
This result is not due to an inactivation of the tPA-plasmin pathway in the SCN of 
VN-/- mice, as 2-antiplasmin inhibits glutamate-induced phase-shifts in VN
-/- 
brain slices. These results are some of the first to demonstrate a role for VN-
mediated effects of PAI-1 in the adult brain. In particular, they are consistent with 
VN acting in the SCN to maintain PAI-1 in its active form, allowing PAI-1 to inhibit 
the glutamate signal-enhancing actions of tPA. Whether the lack of VN alters 
other entrainment processes in the SCN is an issue that will need to be explored 
in future experiments. 
    It is unclear how much attention should be paid to the small phase advance 
induced by 2-antiplasmin applied to VN
-/- brain slices. 2-Antiplasmin treatment 
did not induce a significant effect when applied to wild-type brain slices. It is 
possible that the lack of VN changes SCN neurochemistry enough so that there 
is an increase in basal plasmin activity, which in turn affects circadian clock 
phase. This is a possibility that can be explored more thoroughly in the future. 
    Taken together, these results demonstrate the presence of VN, PAI-1, tPA, 
plasminogen and plasmin in the SCN, and suggest that they interact to regulate 
photic-resetting of the SCN circadian clock. The results support the hypothesis 
that these proteins regulate the conversion of proBDNF to mBDNF in the SCN, 
and that mBDNF availability acts as a gating mechanism for photic phase-
resetting. It is noteworthy that these proteins generally interact extracellularly, 
often bound to the extracellular matrix (Sappino et al., 1993; Carmeliet & Collen, 
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1998; Minor & Peterson, 2002). As such, the consideration of processes that 
modulate SCN circadian clock phase-resetting should be expanded to include 
extracellular as well as intracellular mechanisms. These findings lay the 
groundwork for future investigations into the functions of these proteins in the 
brain and, in particular, their roles in modulating the SCN circadian clock. 
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CHAPTER III 
Endogenous and Glutamate-Modulated Fibrinolytic Protein and 
BDNF Expression in the Mouse Suprachiasmatic Nucleus in 
vitro 
 
 
Abstract 
 
Mammalian circadian rhythms are controlled by a clock located in the 
suprachiasmatic nucleus (SCN). The mechanisms through which light phase-
shifts the SCN circadian clock are similar to those underlying memory formation 
and long-term potentiation (LTP). Several secreted proteins, including tissue-type 
plasminogen activator (tPA), plasminogen, and brain-derived neurotrophic factor 
(BDNF), have been implicated in this process.  These same proteins are 
important for photic phase-shifts of the SCN circadian clock. We have shown that 
tPA, plasmin and BDNF modulate glutamate-induced phase shift in mouse SCN 
in vitro. tPA and plasmin may interact to convert pro-BDNF into m(ature) BDNF. 
We have further shown that the endogenous tPA inhibitor, plasminogen activator 
inhibitor 1(PAI-1), associated with vitronectin, contributes to these processes.  
   Here we used western-blot analyses of SCN tissue maintained in vitro to assay 
the expression patterns of BDNF and fibrinolytic proteins. We find higher tPA, 
plasmin and mBDNF levels in the SCN at night vs. the day. Also, in vitro 
glutamate treatment of SCN tissue during early night increases tPA levels to ~2.5 
times control levels, while similar treatments during late night and mid-day do not 
alter tPA expression. Glutamate treatment in the early night does not alter PAI-1, 
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plasmin and BDNF levels. However, co-treatment with glutamate and PAI-1 
decreases plasmin levels (vs. glutamate treatment alone), while co-treatment 
with glutamate and 2-antiplasmin decreases the amount of pro- and mBDNF in 
the SCN relative to glutamate treatment alone. We also show that mBDNF levels 
are significantly lower in tPA knockout mice during both day and night. Together, 
these results support circadian clock modulation of BDNF and fibrinolytic protein 
levels in the SCN. They also suggest that glutamate modulates tPA expression in 
the SCN, while tPA and plasmin modulate BDNF expression. Overall, these data 
are consistent with the hypothesis that tPA and its associated fibrinolytic proteins 
contribute to photic phase resetting of the SCN circadian clock through 
modulating the activity of BDNF.  
 
Introduction 
 
Synchronization of the mammalian circadian clock located in the SCN to the 
environment occurs largely through photic signaling resulting in glutamate 
release in the SCN, which activates N-methyl-D-aspartate (NMDA) receptors, 
increases postsynaptic Ca2+ influx and activates of nitric oxide synthase (Ding et 
al., 1994). In order for glutamate to phase-shift the clock, the growth factor, brain-
derived neurotrophic factor (BDNF), must concurrently activate its TrkB receptors 
(Liang, et al. 1998, 2000; Michel, et al. 2006; Mou, et al. 2009). Light- and 
glutamate-induced phase-shifts are blocked by a TrkB receptor antagonist and 
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light-induced phase shifts are substantially attenuated in BDNF+/- mice (Liang et 
al., 2000; Michel et al., 2006).  
    Research in the hippocampus has shown that activation of BDNF involves the 
fibrinolytic proteins, tissue-type plasminogen activator (tPA) and plasminogen. 
tPA is an extracellular serine protease that is expressed and secreted in the 
hippocampus in response to glutamate stimulation (Shin et al., 2004). The 
specific downstream target of tPA proteolysis is the zymogen plasminogen. tPA 
converts plasminogen to its active form, plasmin, through proteolytic cleavage 
(Plow et al., 1995). Plasmin then cleaves proBDNF to form mBDNF (Lee et al., 
2001). The tPA-plasmin-BDNF axis has been implicated in the modulation of 
hippocampal synaptic plasticity. Plasminogen+/- mice exhibit severely impaired 
hippocampal LTP that can be rescued by application of mBDNF but not proBDNF 
(Pang et al., 2004). Importantly, it also has been shown that the tPA-plasmin-
BDNF axis modulates glutamate-induced phase-shifts in the SCN (Mou et al. 
2009). 
    In plasma, tPA cleavage of plasminogen is countered by the serine protease 
inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1; Huntington & Carrell, 
2001). PAI-1 is maintained in its active state by binding with vitronectin (VN; 
Podor et al., 2000a, b; Minor & Peterson, 2002; Mayasundari et al., 2004). 
Functional interactions between PAI-1 and VN have been suggested in adult 
mouse SCN: PAI-1 does not inhibit glutamate-induced phase shifts in SCN of 
VN-/- mice as it does in wild type mice (Mou et al. 2009). These data suggest that 
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tPA and plasmin modulate glutamate-induced phase-shifts in the SCN in a PAI-
1/VN-dependent fashion. 
Previous microarray studies have found that VN, PAI-1, tPA and plasminogen 
mRNA are expressed in the SCN (Panda et al. 2002; Menger et al. 2005), with 
tPA and PAI-1 mRNA showing rhythmic expression (Panda et al. 2002; Menger 
et al. 2005). However, the expression patterns of their respective proteins were 
not investigated. Liang et al. (1998) demonstrated that SCN content of both 
BDNF mRNA and protein oscillate in a circadian fashion. BDNF mRNA and 
protein levels reach peak values during the early subjective day and during the 
subjective night, respectively. However, in that study, they did not differentiate 
between proBDNF and mBDNF. Recent studies have illuminated the functional 
distinctions between proBDNF and its cleavage product, mBDNF (see review by 
Lu et al. 2003). Therefore, in this study we investigate the temporal expression 
patterns of these proteins, including differential analysis of pro- and mBDNF. We 
also began investigating the regulation of these proteins in the SCN.  
 
 
Materials and Methods 
 
Brain slice preparation 
 
Coronal brain slices (500 um) containing just the SCN and underlying optic 
chiasm were prepared during the early subjective day from adult male (> 8 weeks 
old) C57BL/6J (Harlan Laboratories) and tPA knockout (tPA-/-) mice housed in a 
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12 : 12 h light : dark cycle.  tPA-/- mice were kindly provided by Dr Mintz at Kent 
State University. They were purchased from The Jackson Laboratory and are on 
a pure C57BL/6J background. tPA-/- mice develop normally; they are fertile and 
have a normal life span. There are no gross histological abnormalities. Mice were 
killed by decapitation. The slices were maintained at the interface of a Hatton-
style brain slice chamber continuously perfused at 37°C with oxygenated (95% 
O2/5% CO2) Earle’s Balanced Salt Solution supplemented with glucose, 
bicarbonate and gentamicin. The pH was adjusted to 7.4 (Prosser, 2003). One 
mouse was used for each experiment, with replicate experiments performed on 
brain slices from different mice. All experimental protocols were approved by the 
University of Tennessee Knoxville Institutional Animal Care and Use Committee. 
 
Drug treatments 
 
All treatments were bath-applied on the first day in vitro. To apply the treatments, 
perfusion of the brain slice chamber was stopped, and the medium in the 
chamber was replaced with medium containing the appropriate compounds. 
Glutamate application was for 10 min, beginning at Zeitgeber time 6, 16 or 23 
(ZT6, ZT16 or ZT23, where ZT0 corresponds to lights on and ZT12 corresponds 
to lights off in the donor animal colony). In experiments involving compounds 
other than glutamate, the slices were pre-treated with the other substances alone 
for 30 min and then were co-treated with glutamate for 10 min. At the end of the 
treatments, slices were removed and frozen in extraction buffer for later protein 
analysis.  
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Western blots 
 
To assess in vivo protein expression, SCN tissue was dissected from mouse 
brains as described above and immediately frozen for later Western blot assay 
as described before (Mou et al. 2009). To assess in vitro protein expression, 
SCN brain slices were prepared and maintained in the slice chamber for 
harvesting at the appropriate time. In all cases, harvested tissue was 
homogenized in ice-chilled HEPES-based extraction buffer containing a protease 
inhibitor cocktail (1 mM phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin, 15 
mg/mL leupeptin, 10 mg/mL pepstatin). For BDNF immunoblots, tissue was 
prepared in Tris-based denaturing extraction buffer [4M urea, 0.02M 
dithiothreitol, 0.05M Tris, pH 7.4, 2% sodium dodecyl sulfate (SDS)]. The tissue 
extract sample was separated into aliquots and stored at -80°C. Protein content 
of the extract was determined by the bicinchoninic acid method (BCA; Pierce). 
Tissue samples were mixed with loading buffer (pH 6.8 Tris, SDS, bromophenol 
blue, glycerol), and subjected to SDS–polyacrylamide gel electrophoresis 
(PAGE). Proteins were electrotransferred onto nitrocellulose membranes, which 
were then incubated with blocking buffer [10% solution of non-fat dry milk in 
phosphate-buffered saline with Tris (PBST)]. The membranes were probed with 
primary antibodies diluted in a 2.0% solution of non-fat dry milk in PBST, followed 
by goat anti-rabbit horseradish peroxidase-conjugated secondary antibody at 
appropriate dilutions in the same buffer. Signals were revealed by enzyme-
catalysed chemiluminescence (Pierce, IL, USA). The amount of protein loaded in 
each lane was assessed by probing for actin or -tubulin, so all protein 
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expression is reported as levels relative to actin or -tubulin. Control experiments 
included running parallel lanes loaded with the corresponding native proteins 
(positive controls), and probing membranes with primary antibodies pre-
incubated with the native protein to test for cross-reactivity and to establish the 
specificity of the antibody samples. Rabbit anti-plasminogen, anti-tPA, anti-PAI-1 
and anti-VN antibodies were obtained from Molecular Innovations (Detroit, MI, 
USA). Rabbit anti-actin and anti--tubulin antibodies were obtained from Santa 
Cruz Biochemicals (Santa Cruz, CA, USA). Rabbit anti-proBDNF antibody was 
obtained from Millipore (MA, USA) and rabbit anti-BDNF antibodies were from 
Alomone Labs (Jerusalem, Israel). 
Statistical analysis 
 
One-way ANOVA was used to test for significant differences among protein 
levels for 24 hour rhythm. . Student’s t-test was used to test differences in protein 
levels between two groups. Post-hoc Tukey tests were used for multiple 
comparisons among more than two groups. Significance was set at p<0.05. 
 
 
 
Results 
 
In vitro expression patterns of BDNF and fibrinolytic proteins in the SCN 
 
We have shown that BDNF, VN, PAI-1, tPA and plasmin(ogen) are all expressed 
in mouse SCN (Mou et al. 2009). Here we examined their temporal expression 
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patterns. Brain slices containing the SCN from WT mice were prepared and 
maintained in vitro. At three hour intervals, slices were removed and stored at -
80°C for later homogenization and protein analysis.  
We differentiated between pro- and mBDNF proteins by using respectively 
specific antibodies as well as by their distinct sizes. proBDNF was identified as 
~37kD bands, while mBDNF ~15kD bands.  Although proBDNF levels relative to 
-tubulin appear to increase during the subjective day and decrease during 
subjective night, there was no statistically significant change in proBDNF levels 
across time (one-way ANOVA, p=0.95, Fig. 10). Even when the data for the 4 
highest time points (ZT6-ZT 18) were pooled and compared to the pooled lowest 
values  (ZT18-ZT6), there was no significant  difference (p=0.16). Conversely, 
mBDNF levels in the mouse SCN exhibited significant changes over the course 
of the 24 hours (one-way ANOVA, p<0.05, Fig. 11). The SCN content of mBDNF 
was low throughout the daytime, rose to a peak around ZT12, then declined 
during the subjective night. Overall, there was about a 2.5 fold difference 
between the minimum and maximum levels. Levels of mBDNF in the SCN pooled 
across the late subjective day to subjective night (ZT11-ZT20) were significantly 
greater than those pooled from the late subjective night to subjective day (ZT23-
ZT8) (Student’s t-test, p<0.05). To increase temporal resolution of the changes in 
mBDNF levels, the data were pooled into four groups (represented by red 
horizontal bars in Fig. 11). mBDNF levels during ZT11 to ZT14 were significantly 
higher than those during ZT5 to ZT8 and ZT23 to ZT2 (post hoc Tukey test, 
p<0.05). 
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The SCN content of tPA also exhibited a fluctuation across 24 hours. tPA 
levels pooled across the subjective night (ZT14-ZT24) were significantly greater 
than those throughout the subjective day (ZT4-ZT12) (Student’s t-test, p<0.05, 
Fig. 12). 
There was also a fluctuation in the SCN content of plasmin. Plasmin levels 
pooled across the subjective night (ZT14-ZT23) were significantly greater than 
those throughout the subjective day (ZT0-ZT11) (Student’s t-test, p<0.05). Again, 
the data were pooled into four groups as for mBDNF. Plasmin levels during ZT17 
to ZT20 were significantly higher than those during ZT5 to ZT8 (post hoc Tukey 
test, p<0.05, Fig. 13). 
Temporal expression patterns for PAI-1 and VN, were assessed at 6 hour 
intervals. As shown in Figure 14, PAI-1 levels exhibited changes across the 24 
hours. Analysis of the pooled data indicated that PAI-1 levels during subjective 
day (ZT5-ZT11) were greater than those during the night (ZT17-ZT23) (Student’s 
t-test, p<0.05). Conversely, VN levels did not show significant changes across 
the 24 hours (one-way ANOVA, p=0.57) or when the data were pooled into 
highest and lowest 12-h intervals (ZT11-ZT17 vs. ZT23-ZT5; p=0.24, Fig. 15).  
The protein changes observed in the SCN in vitro are summarized in Figure 
16A.  As a comparison, the times of peak mRNA expression as reported in 
previous studies (Liang et al., 1998; Menger et al., 2005) are shown in Figure 
16B.  
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Figure 10. In vitro expression of proBDNF protein in the mouse SCN.  Plotted are 
the protein levels relative to -tubulin at 3 hours intervals with SEM (n = 3 for 
each time point). One-way ANOVA indicated no significant differences across 
time (p=0.95). Post hoc Student’s t-test of samples pooled from ZT6-ZT18 vs. 
ZT18-ZT6 also indicated no significant difference (p=0.16). Black horizontal bar: 
lights-off in the animal colony. 
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Figure 11. In vitro expression of mBDNF protein in the mouse SCN.  (A) Western 
blot result of mBDNF time course. (B) Plotted are the protein levels relative to -
tubulin at 3 hours intervals with SEM (n = 3 for each time point). The data were 
pooled into four groups, represented by red horizontal bars. *mBDNF levels 
during ZT11 to ZT14 were significantly higher than those during ZT5 to ZT8 and 
ZT23 to ZT2 (post-hoc Tukey test, p<0.05). Black horizontal bar: lights-off in the 
animal colony. 
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Figure 12. In vitro expression of tPA protein in the mouse SCN.  (A) Western blot 
result of tPA time course. (B) Plotted are the protein levels relative to actin at 3 
hours intervals with SEM (n = 3 for each time point). The data were pooled into 
two groups, represented by red horizontal bars. *tPA levels during ZT12 to ZT24 
were significantly higher than those during ZT0 to ZT12 (Student’s t-test, p<0.05). 
Black horizontal bar: lights-off in the animal colony. 
 
 
Zeitgeber time (hr)
0 6 12 18 24
tP
A
 r
e
la
ti
v
e
 d
e
n
s
it
y
0
1
2
3
4
*
  61 
A: 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. In vitro expression of plasmin protein in the mouse SCN.  (A) Western 
blot result of plasmin time course. (B) Plotted are the protein levels relative to 
actin at 3 hours intervals with SEM (n = 3 for each time point). The data were 
pooled into four groups, represented by red horizontal bars. *plasmin levels 
during ZT17 to ZT20 were significantly higher than those during ZT5 to ZT8 
(post-hoc Tukey test, p<0.05). Black horizontal bar: lights-off in the animal 
colony. 
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Figure 14. In vitro expression of PAI-1 protein in the mouse SCN.  (A) Western 
blot result of PAI-1 time course. (B) Plotted are the protein levels relative to actin 
at 3 hours intervals with SEM (n = 3 for each time point). The data were pooled 
into two groups, represented by red horizontal bars. *PAI-1 levels during ZT0 to 
ZT12 were significantly higher than those during ZT12 to ZT24 (Student’s t-test, 
p<0.05). Black horizontal bar: lights-off in the animal colony. 
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Figure 15.  In vitro expression of vitronectin protein in the mouse SCN.  Plotted 
are the protein levels relative to actin at 3 hours intervals with SEM (n = 3 for 
each time point). One-way ANOVA indicated no significant differences across 
time (p=0.57). Post hoc Student’s t-test of samples pooled from ZT11-ZT17 vs. 
ZT23-ZT5 also indicated no significant difference (p=0.24). Black horizontal bar: 
lights-off in the animal colony. 
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Figure 16.  Times of highest protein expression levels and their mRNA in the 
SCN. A) Horizontal bars indicate the time spans during which the individual 
proteins exhibited their highest values in our experiments. B) Horizontal bars 
indicate the time spans within which individual mRNA exhibited their highest 
values, as reported previously (Liang et al., 1998; Menger et al., 2005). 
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In vitro modulation of SCN protein expression 
 
We next investigated whether glutamate can modulate the expressions of tPA, 
plasmin, proBDNF or mBDNF in the SCN in vitro. For these experiments, brain 
slices containing the SCN were prepared and maintained in vitro. Depending on 
the experiment, glutamate was either applied alone for 10 min or introduced with 
other compounds at ZT6, 16 or 23. Tissue slices were then harvested for protein 
analysis. Glutamate treatment in the early night (ZT16) increased tPA levels to 
~2.5 times control levels (p<0.05, n=5), while treatment in the late night (ZT23) 
and in the daytime (ZT6) did not significantly alter tPA expression (Fig. 17). 
Glutamate treatment alone at ZT16 did not alter expression of plasmin, proBDNF 
or mBDNF (Fig. 18). Interestingly, pre-treating SCN tissue for 30 min with PAI-1 
followed by co-treatment with glutamate and PAI-1 at ZT16 decreased the 
amount of plasmin in the SCN relative to glutamate treatment without affecting 
the levels of pro- and mBDNF (Fig. 18A). Conversely, pre-treating SCN tissue for 
30 min with 2-antiplasmin followed by co-treatment with glutamate and 2-
antiplasmin at ZT16 decreased the amount of pro- and mBDNF in the SCN 
relative to glutamate-treatment alone without affecting plasmin levels (Fig 18B).  
 
BDNF expression in the SCN of tPA knockout mice 
 
Based on our previous research (Mou et al. 2009), we hypothesized that tPA 
functions in the SCN to increase mBDNF production. Here we tested this 
hypothesis by examining in vivo mBDNF and proBDNF protein expression in  
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Figure 17. Effect of in vitro glutamate treatment on tPA expression in the SCN at 
different times.  10 min glutamate treatment significantly increased tPA levels in 
early night (ZT16) relative to control (no treatment), but not in late night (ZT23) or 
in daytime (ZT6). (Student’s t-test, *p<0.05) 
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Figure 18. In vitro Glutamate modulation of plasmin and BDNF expression in 
SCN slices at ZT16. (A) Glutamate+PAI-1 treatment significantly decreased 
plasmin expression relative to glutamate treatment alone, but did not affect the 
levels of pro- and mBDNF. (B) Glutamate + 2-antiplasmin treatment decreased 
the amount of pro- and mBDNF relative to glutamate treatment alone, but did not 
affect plasmin levels. (Student’s t-test, * p<0.05) 
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SCN tissue from tPA knockout mice (tPA-/-). 
    For these experiments, SCN tissue was isolated from WT and tPA-/- mice and 
immediately transferred into extraction buffer for protein analysis. Based on the in 
vitro circadian expression pattern of mBDNF in WT mice shown earlier, we chose 
to assay pro- and mBDNF levels at two time points, ZT4 and ZT12, when 
mBDNF displayed the lowest and highest levels respectively. SCN content of 
pro- and mBDNF from tPA-/- and WT mice was quantified and normalized to -
tubulin.  Then a mBDNF to proBDNF ratio was computed as the index for relative 
mBDNF quantity. Comparative analysis showed that mBDNF/proBDNF levels in 
WT mice were significantly higher than in tPA-/- mice at ZT4 (p<0.05) and there 
was a trend towards being significantly higher at ZT12 (p=0.06) (Fig. 19).   
It was noted that the in vitro rhythm in mBDNF levels, with highest expression 
at ZT11, observed in WT SCN tissue (Fig. 10), was not seen in this experiment 
for either WT or tPA-/- mice (data not shown).  This difference could be attributed 
to the difference in tissue harvesting protocol in the two experiments. In this 
case, SCN tissue from tPA-/- mice was harvested immediately after slice 
preparation. Another set of experiments was conducted to test this possibility. 
One set of brain slices containing the SCN from WT mice was prepared at ZT1 
and maintained undisturbed in the slice chamber for later harvesting and 
homogenization at either ZT4 or ZT12. In parallel, a second set of slices was 
prepared at ZT4 and ZT12 and harvested immediately without incubation in the 
slice chamber. Protein quantities were assayed as before. As shown in Fig. 20, 
mBDNF protein expression is substantially higher, although not reaching statistic 
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significance, at ZT12 than at ZT4 in SCN slices maintained in vitro (p=0.06), 
while mBDNF levels are essentially unchanged between ZT4 and ZT12 in SCN 
tissue harvested immediately after slice preparation (p=0.30).  
 
Discussion 
 
Having previously demonstrated the critical involvement of tPA and its associated 
proteins in glutamate-induced phase resetting of the mouse SCN circadian clock, 
in this study we wished to characterize the expression patterns of these proteins. 
We began by examining the in vitro temporal pattern of protein expression in the 
SCN from WT mice. We found significant rhythms in PAI-1, tPA, plasmin and 
mBDNF levels, while we found no rhythm in proBDNF and VN protein expression 
in the SCN.     
    Our data on mBDNF and proBDNF are interesting in light of a previous study 
investigating BDNF expression in SCN (Liang et al. 1998). In that study, BDNF 
protein levels in the rat SCN (not differentiating between pro- and mBDNF) were 
found to peak around CT16, while BDNF mRNA levels were shown to peak 
approximately 16 hour earlier, around CT0. Our results showing high mBDNF 
levels in early subjective night fit well with their data. Combined with our data 
showing a lack of temporal changes in pBDNF, this suggests that the rhythmic 
expression pattern of BDNF observed in their study may in fact correspond to  
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Figure 19. Modulation of BDNF expressions by tPA. Shown are mBDNF to 
proBDNF ratios for WT and tPA-/- mice at ZT4 and ZT12. *mBDNF/proBDNF ratio 
for WT mice is higher than that for tPA-/- mice at ZT4 (p<0.05) and at ZT12 
(p=0.06). 
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Figure 20. Tissue harvesting protocol affects mBDNF level. Shown are mBDNF 
to -tubulin ratios for WT mice at ZT4 and ZT12. *Relative mBDNF levels of 
tissue maintained in vitro showed a trend towards a significant difference 
(p=0.06), while those harvested without incubation did not (p=0.30). 
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mBDNF.  On the other hand, since proBDNF levels in our study show a trend 
somewhat in parallel with that of mBDNF, we cannot rule out the possibility that 
the previous study measured both mBDNF and proBDNF.  Unfortunately, they do 
not indicate what size protein they were quantifying, so this cannot be verified. 
    The circadian regulation of mBDNF expression provides an endogenous 
mechanism for SCN cells to gate their sensitivity to photic/glutamate stimuli. 
Elevated SCN levels of mBDNF during the subjective night coincide with the 
critical time window when light and glutamate can induce phase shifts in the SCN 
pacemaker. Conversely, expression of mBDNF remains at basal levels 
throughout the subjective day when the SCN cells are insensitive to 
light/glutamate stimuli (Ding et al., 1998; Liang et al., 2000). The potential for 
mBDNF to act as a photic gating mechanism is reinforced by data showing that 
chronic infusion of BDNF into the SCN allows light induced phase shift in the 
subjective day (Liang et al., 2000).  Likewise, daytime treatment of SCN brain 
slices with glutamate and BDNF can phase-advance the SCN clock, while 
glutamate treatment alone at that time normally has no resetting action (Mou et 
al., 2009).  
The relatively low tPA protein expression in the SCN during the daytime is also 
consistent with our hypothesis that circadian clock sensitivity to photic stimuli is 
modulated by mBDNF availability, and that tPA participates in regulating mBDNF 
levels. These data are also consistent with our earlier results showing that co-
treatment of SCN brain slices with glutamate and tPA at ZT6 induced a phase 
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advance (Mou et al., 2009). Thus, daytime treatment with tPA may lead to higher 
daytime BDNF levels, which then allows (gates) glutamate-induced phase shifts.  
The high tPA levels we observed at night are also consistent with our results 
showing: first, that plasmin protein levels are high in the SCN at night in parallel 
with increased tPA levels; second, that PAI-1 treatment at ZT 16, when tPA 
levels are high, decreases plasmin expression in the SCN; and third, that 
nighttime treatment with PAI-1 blocks glutamate-induced phase shifts in vitro 
(Mou et al. 2009). To confirm the functional nature of these changes in tPA, 
however, it would be worthwhile to follow up these experiments on protein 
expression with experiments investigating differences in protein activity.  
A previous study has shown that tPA exhibits highest mRNA abundance 
during late day (Menger et al., 2005). Our results showing that tPA protein has 
higher expression during the night (Fig. 16), suggests that tPA translation follows 
transcription with a few hours delay.  Although tPA transcription and translation 
are known to be activated by glutamate receptor stimulation (Shin et al., 2004), 
additional research is needed to determine what regulates these processes in the 
SCN.    
In our experiments, we also observed higher PAI-1 protein expression during 
the day than the night. Lower PAI-1 protein expression during the night is 
consistent with higher tPA activity in the SCN during night, as could be reflected 
by the higher plasmin and mBDNF levels in the SCN at night. Interestingly, a 
previous study found out that PAI-1 mRNA in the SCN has its highest expression 
  74 
during early night (Panda, 2002). This suggests there may be a 12 h delay 
between PAI-1 transcription and translation. Similar differences in mRNA and 
protein levels are seen with other circadian clock proteins in the SCN (Liang et 
al., 1998). 
tPA and PAI-1 also fluctuate in a circadian manner In the periphery. PAI-1 
activity in plasma is significantly higher humans in the morning, concurrent with 
lower tPA activity (Angleton et al., 1989). These circadian fluctuations parallel the 
higher onset of acute atherothrombotic events. For example, increased morning 
PAI-1 activity in humans is associated with early morning hypofibrinolysis 
(Kurnik, 1996), which could contribute to the morning onset of stroke. Our results 
showing higher PAI-1 expression starting in the early morning actually are 12h 
out-of-phase with these results in humans, since early morning in mice is the 
onset of their inactive phase. However, there is precedence for peripheral 
gene/protein expression being out-of-phase with respect to SCN expression 
(Hasting et al., 2003; Schibler et al., 2003). Interestingly, PAI-1 expression is 
under transcriptional regulation by the heterodimer of circadian clock genes, 
Clock/Bmal, that activate E-box enhancers in the PAI-1 promoter (Schoenhard et 
al., 2003). The circadian expression pattern of PAI-1 mRNA is lost in the Clock 
mutant mouse (Minami et al., 2002). Thus, clock gene products may drive the 
circadian variation in PAI-1 expression, which in turn can influence the timing of 
fibrinolysis in the periphery, and photic phase resetting in the SCN.  
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In addition to their potential regulation by the circadian clock, we also show 
that tPA, plasmin and BDNF levels in the SCN can be altered by application of 
endogenous modulators. Glutamate treatment increased tPA expression, but 
only when applied during early night. Whether this time-dependency is due to a 
lack of tPA mRNA available at other circadian times or whether other factors limit 
tPA induction is not known. Conversely, the other proteins assayed (plasmin, 
pro- and mBDNF) were not affected by glutamate treatment alone. It is quite 
possible that these negative results are attributable to the short treatment time 
frame used (10min).  This brief period may have been insufficient for changes in 
(tPA) protein expression to be translated into changes in downstream proteolytic 
processes. Subsequent studies should be conducted to examine glutamate 
effects on protein levels after longer time periods.   
Following up on these results, it is interesting that a 30 min pre-treatment with 
PAI-1 followed by glutamate at ZT16 decreased plasmin expression in the SCN. 
These data are consistent with an ongoing tPA-induced conversion of 
plasminogen to plasmin in the SCN occurring during early night that can be 
inhibited by PAI-1. While pro- and mBDNF levels were not changed by this 
treatment, again it is possible that changes in these proteins, being further 
downstream from tPA regulation, might have been seen after a longer post-
treatment period. Consistent with this possibility, decreased mBDNF expression 
was observed when plasmin was directly inhibited by 2-antiplasim, an inhibitor 
more proximate to proBDNF cleavage to mBDNF.  On the other hand, it was 
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surprising that proBDNF expression also decreased under 2-antiplasim 
treatment, since the decrease in mBDNF production ought to be associated with 
an increase in proBDNF levels. A more thorough analysis of the changes in 
protein expression in the SCN might resolve this issue. 
 We also show that mBDNF/proBDNF ratios are significantly lower in tPA-/- 
mice. These data lend further support to the hypothesis that mBDNF production 
in the SCN is regulated by tPA. One might predict, based on these results, that 
tPA-/- mice would exhibit deficits in photic entrainment, similar to their deficits in 
hippocampal LTP, that can be reversed by either plasmin or mBNDF treatment 
(Pang et al., 2004).     
One important issue that remains to be addressed is whether there is a rhythm 
in the secretion of BDNF and other proteins in the SCN. In general, cellular 
secretion of BDNF is thought to parallel neuronal activity (Balkowiec et al., 2000; 
Level et al., 2001; Luo et al., 2001; Kuczewski et al., 2009). If this were true in 
the SCN, then one would see higher BDNF secretion in the day, when SCN 
neuronal activity peaks. In the hippocampus, proBDNF conversion to mBDNF 
appears to occur primarily extracellularly (Lee et al., 2001). Furthermore, tPA and 
plasminogen are thought to be secreted from neurons in parallel with BDNF.  So 
the question becomes: do the rhythms in protein expression seen here reflect 
rhythms in protein production, and/or rhythms in secretion?  Our data showing a 
decrease in mBDNF levels after 2-antiplasmin treatment suggests that, in the 
SCN, proBDNF is converted to mBDNF extracellularly through proteolytic 
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cleavage by plasmin. However, we still know little about the secretory dynamics 
associated with the changes we have observed. This issue could be addressed 
using a cell culture system where intracellular and extracellular protein 
expression can be assessed separately.  
Finally, as mentioned earlier, the experiments presented here do not address 
the critical issue of potential rhythms in protein activity. While one can speculate 
that activity rhythms will parallel those of the proteins, the existence of multiple 
modulations associated with these proteins make such speculation somewhat 
tentative.  
    Taken together, these results provide support for circadian clock regulation of 
BDNF, tPA, plasmin, and PAI-1, but not VN protein expression in the mouse 
SCN. They further suggest that glutamate modulates tPA expression in the SCN 
during early night, tPA modulates plasmin production, and plasmin in turn 
modulates mBDNF expression. Together, these results are consistent with the 
hypothesis that the tPA/plasmin axis functions in the SCN to activate BDNF, 
thereby gating the ability of the SCN clock to be modulated by photic input.  
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CHAPTER IV 
Conclusions and Future Directions 
 
A Working Model for Glutamate-induced Phase Shifts in mouse 
SCN 
 
Based on our results in chapter 2 and 3, a working model for glutamate-induced 
phase shifts in the SCN was created and illustrated in Fig. 21. Vitronectin and 
plasminogen expressions do not display significant rhythmic patterns throughout 
24 hours. Given high PAI-1 levels and low tPA level during the day, plasmin and 
mBDNF cannot be converted from their respective precursors in sufficient 
quantity. Without enough mBDNF activating its TrkB receptors, enhancement of 
glutamate activity cannot occur, therefore no glutamate-induced phase shifts will 
take place during daytime (Fig. 21A). However, adding exogenous tPA or 
mBDNF during the day can overcome these insufficiencies, thereby allowing 
daytime phase shifts by glutamate. 
    Conversely, tPA levels are high during night and PAI-1 levels are low. This 
combination allows increased production of plasmin and mBDNF. The increased 
mBDNF production activates TrkB receptor , which enhances glutamate signaling 
and allows glutamate- induced phase shifts (Fig. 21B). 
 
BDNF Could Regulate the Expression/activity of NMDA 
Receptors 
 
        BDNF has been shown to play multiple important roles in NMDA receptor- 
mediated hippocampal LTP (reviewed in Bramham and Messaoudi, 2005). The 
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A: Day: low tPA, plasmin, and mBDNF levels 
 
 
 
 
 
 
 
 
 
B: Night: high tPA, plasmin, and mBDNF levels 
 
 
 
 
 
 
 
 
Figure 21. Model of extracellular gating of photic phase resetting of the SCN 
circadian clock. A: high PAI-1 and low tPA during the day result in low mBDNF 
generation, therefore no glutamate phase shifts are induced. B: Glutamate-
induced phase shifts are induced during night when tPA activity is not inhibited 
by PAI-1, which leads to higher mBDNF production 
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rapid effects of BDNF on postsynaptic responses to glutamate have been largely 
attributed to phosphorylation of NMDA receptor subunits, which increases 
receptor activity (Levine et al. 1998; Levine and Kolb, 2000). This effect may 
involve BDNF-TrkB-Src like kinases.   
   BDNF may also alter the availability of NMDA receptor subunits. Caldeira et al. 
(2007) showed that in a hippocampal cell culture system, BDNF induces a rapid 
delivery of NR2B-containing NMDA receptors to the plasma membrane, which 
correlates with an increase in intracellular Ca2+ concentration. They also showed 
that BDNF increases mRNA levels for NR1, NR2A and NR2B subunits. Given the 
abundance of BDNF and TrkB receptors in the SCN, and their colocalization with 
NMDA receptors, it would not be surprising if BDNF upregulates NMDA receptor 
phosphorylation and/or expression in the SCN. In vitro immunohistochemistry 
could be used to address this question.   
Given the demonstrated importance of BDNF for LTP, one question is where 
the BDNF is coming from. Marini et al. (1998) showed that in cerebellar granule 
cell culture, exposure of granule cells to NMDA evoked an accumulation of BDNF 
in the medium without concomitant changes in the intracellular levels of BDNF 
protein or mRNA. The increase in BDNF in the medium was followed by 
enhanced TrkB tyrosine phosphorylation. This coactivation of NMDA and TrkB 
receptors can occur within ten minutes. This time-course is consistent with 
BDNF’s importance for the initial stage of LTP. It is not clear whether NMDA 
receptor activation induces BDNF release in SCN. If it does, a mutual facilitation 
between glutamate/NMDA and BDNF/TrkB signaling could amplify the effects 
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exerted by each acting alone.  Using cell culture could help reveal changes in 
extracellular vs. intracellular BDNF levels. 
 
BDNF Effects on Presynaptic Cells 
 
    In our model, BDNF facilitates photic/glutamate induced phase shifts in the 
SCN by enhancing the signaling of postsynaptic NMDA receptors. However, the 
facilitating effects of BDNF are not limited to postsynaptic cells. In the visual 
cortex and hippocampus, BDNF can also potentiate neuronal signaling by 
enhancing transmitter release from presynaptic neurons (Levine et al., 1995; 
Carmignoto et al., 1997; Tanaka et al., 1997). BDNF could likewise modulate 
responses of SCN neurons to photic input via enhancing presynaptic release of 
neurotransmitter from RHT terminals. Evidence for this comes from a study 
showing that BDNF enhances spontaneous excitatory postsynaptic potentials in 
SCN cells in vitro (Michel et al. 2006). However, given that BDNF treatment 
alone during the day does not induce a phase shift (Liang et al., 2000; Mou et al., 
2009), this indicates that the amount of glutamate released in response to BDNF 
is insufficient to alter clock phase.  
    BDNF could also act in the SCN through modulating GABA neurotransmission. 
BDNF has been shown to attenuate the responses of GABA receptors to GABA 
applied to rat hippocampal neurons (Tanaka et al., 1997). Since GABA is the 
predominant neurotransmitter in the SCN (Moore and Speh, 1993; Liu et al., 
1994), and GABAergic agents alter the phase-shifting effects of light on circadian 
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rhythms (Ralph and Menaker, 1989; Golombek and Ralph, 1994), BDNF could 
act via the GABAergic transmission system to regulate photic resetting of the 
SCN pacemaker. Experiments investigating SCN phase shifts when BDNF and 
GABA are coapplied could address this question. 
 
BDNF mRNA Alternatives 
 
    Like other neuropeptides, BDNF is synthesized as a pre-proprotein that 
undergoes further splicing and modification at multiple steps. While not 
distinguished in our study, multiple BDNF transcripts exist. Mouse and rat BDNF 
genes consist of four 5’ noncoding exons (I, II, III, or IV) and one protein coding 
3’ exon. Transcription of the gene results in BDNF transcripts containing one of 
the four 5’ exons spliced and the 3’ protein coding exon. BDNF gene expression 
is controlled by multiple activity-dependent and tissue-specific promoters. Four 
BDNF promoters have been previously identified in rat (Timmusk et al., 1993; 
Timmusk et al., 1995), each driving the transcription of BDNF mRNAs containing 
one of the four 5’ noncoding exons spliced to the common 3’ coding exon.  In 
addition, transcription factors, such as CREB and calcium-responsive 
transcription factor (CaRF), have been found to modulate BDNF transcription 
through binding to different BDNF promoters (Tao et al., 1998; Tabuchi et al., 
2002; Tao et al., 2002). Chromatin remodeling by DNA methylation and histone 
deacetylation also plays an important role in cell-specific and activity-dependent 
regulation of BDNF (Timmusk et al., 1999; Zuccato et al., 2003). Because 
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alterations in BDNF expression in specific neuron subpopulations contribute to 
various nervous system pathologies, including depression, epilepsy, and 
Alzheimer’s, Huntington’s, and Parkinson’s diseases (Bibel and Barde, 2000; 
Binder and Scharfman, 2004; Castren, 2004; Russo-Neustadt and Chen, 2005), 
it would be interesting to determine which BDNF transcript(s) are involved in 
circadian clock resetting in the SCN. 
 
Localization of Fibrinolytic Proteins and Their Activity 
 
        From the data presented earlier, it is clear that fibrinolytic proteins regulate 
the generation of mBDNF, and thus modulate glutamate-induced SCN clock 
resetting. However, the localization and compartmental distribution of those 
proteins within the SCN remains unclear. The mechanisms through which 
fibrinolytic proteins exert their activities can vary depending on their localization 
and binding partners. For example, in addition to regulating plasmin generation, 
the VN-PAI-1 complex interacts with extracellular matrix (ECM) proteins. Through 
this interaction, VN localizes PAI-1 to specific extracellular loci to modulate 
migration and proliferation. However, there has been little investigation into the 
location of VN and PAI-1 in the brain. Likewise, tPA and plasmin localization and 
activity in the brain is largely uncharacterized, in particular as to whether their 
localization and/or activity are altered by neuronal stimulation.   
    The best system to investigate the compartmental location of the fibrinolytic 
proteins and their activity is one where the cells, extracellular fluid and ECM can 
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be separated.  The SCN2.2 cell line is such a system to achieve this goal. This 
immortalized cell line has been studied extensively in the mammalian circadian 
system. These cells express many of the functional characteristics of the intact 
SCN, they generate circadian rhythms, and they respond to phase-resetting 
stimuli found to reset the intact SCN (Allen and Earnest, 2002; Rivera-Bermudez 
et al., 2003; Menger et al., 2005; Nahm et al., 2005).  Recently, we have shown 
in our lab that all the fibrinolytic proteins and BDNF are expressed within all three 
tissue compartments (cells, medium, and ECM) in the SCN2.2 cell culture 
(abstract, Cantwell et al., 2008).  The next step is to determine the temporal and 
spacial distribution of their enzymatic activities, and determine which fibrinolytic 
protein binding partners are critically involved in regulating BDNF activity. 
 
 
Plasmin-independent Effects of tPA 
 
    In addition to activating plasmin, many tPA effects in the central nervous 
system are plasmin-independent. One molecule with which tPA directly interacts 
to enhance LTP is the NR1 subunit of the NMDA receptor. Using a neuronal cell 
culture model, Nicole et al. (2001) reported that tPA cleaves NR1, thereby 
enhancing NMDA-mediated intracellular calcium levels and neuronal 
degeneration. However, the direct cleavage of NR1 by tPA has not been 
observed in other studies (Matys and Strickland, 2003; Liu et al., 2004). An 
interaction between tPA and the NR2B subunit has been reported during ethanol 
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withdrawal-induced seizures (Pawlak et al. 2005). In the amygdala, the function 
of tPA during stress-induced anxiety also seems to be independent of plasmin 
production (Pawlak et al. 2003). These lines of evidence suggest that tPA can 
function either as a protease or a modulator of cell signaling, and that PAI-1 can 
influence both of these activities. Whether plasmin-independent effects of tPA 
occur in the SCN has not been investigated. 
 
 
Neuroserpin 
 
    As mentioned earlier, neuroserpin is an inhibitor of tPA found exclusively in the 
central nervous system. The degree to which tPA is regulated by neuroserpin vs. 
PAI-1 in the brain has not been investigated. In the adult nervous system, 
neuroserpin is detected in neurons in the same places where tPA is detected, 
such as hippocampus, hypothalamus, cerebellum, amygdala, and sympathetic 
nerves (Krueger, 1997).  
   Neuroserpin has been suggested to play a variety of roles in the CNS. It is 
rapidly released from cells in response to neuronal depolarization, indicating the 
presence of a storage pool that, as with tPA, is ready to be released in response 
to stimuli (Yepes and Laurence, 2004). In vitro studies have shown an activity-
dependent upregulation of neuroserpin in the hippocampus (Berger et al., 1999).  
Animals either lacking or over-expressing neuroserpin exhibit reduced locomotor 
activity in novel environments and anxiety-like responses (Madani et al. 2003). In 
mice, neuroserpin plays a critical role in the development of the primary visual 
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cortex (Wannier-Morino et al., 2003).  Early after the onset of cerebral ischemia, 
there is a transient increase in tPA activity, followed by a surge in neuroserpin in 
the ischemic area (Yepes et al., 2000; 2004). Also, neuronal depolarization 
results in secretion of tPA and an increase in the neuronal transcription of 
neuroserpin (Berger et al., 1999).  
    Neuroserpin reacts ~30-fold slower with tPA than does PAI-1 (Hastings et al., 
1997). Nevertheless, given its general co-expression with tPA in the brain, it 
would be interesting to investigate its role in regulating the SCN clock. 
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